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Marijuana (cannabis) remains a controversial drug in the twenty-first century. This paper
considers current research on use of Cannabis sativa and its constituents such as the
cannabinoids. Topics reviewed include prevalence of cannabis (pot) use, other drugs con-
sumed with pot, the endocannabinoid system, use of medicinal marijuana, medical adverse
effects of cannabis, and psychiatric adverse effects of cannabis use.Treatment of cannabis
withdrawal and dependence is difficult and remains mainly based on psychological therapy;
current research on pharmacologic management of problems related to cannabis consump-
tion is also considered. The potential role of specific cannabinoids for medical benefit will
be revealed as the twenty-first century matures. However, potential dangerous adverse
effects from smoking marijuana are well known and should be clearly taught to a public
that is often confused by a media-driven, though false message and promise of benign pot
consumption.
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INTRODUCTION
A number of chemicals are inhaled for the development of
euphoria, including marijuana (cannabis, pot), methampheta-
mine, heroin, crack cocaine, phencyclidine, and nitrites (amyl
and butyl) (1). Marijuana (cannabis, pot) has been known to
Homo sapiens for thousands of years and concern has been
raised over the past two centuries regarding its potential adverse
effects – leading to various laws in the United States and other
countries to control its production and use (2) (see the Pref-
ace). The psychoactive chemical, delta-9-tetrahydrocannabinol
(THC) was isolated in the mid-1960s while other aspects of the
endocannabinoid system [cannabinoid receptors (CB1 and CB2)
and key endogenous cannabinoids (2-arachidonoyl glycerol and
anandamide)] were identified over 20 years later. Though use
of phytocannabinoids are being increasing linked to improve-
ment of some health conditions, frequent users of cannabis are
at increased risk for adverse effects which can lead to addi-
tional health problems (3). Research is identifying components
of cannabis which are not psychoactive and may become estab-
lished parts of the pharmacopeia as the twenty-first century
continues.
CANNABIS SATIVA PLANT
The products of cannabis are made from the easily grown hemp
plant, Cannabis sativa, and the psychoactive ingredient, delta-9-
THC, is at the heart of the complex cannabis controversy in this
and the past century. The euphoria can last minutes to hours.
The enzyme, ∆1-tetrahydrocannabinolic acid synthase, catalyzes
the oxidative cyclization of cannabigerolic acid (CBGA) into ∆1-
tetrahydrocannabinolic acid, which is the precursor of THC (4).
This enzyme controls the psychoactivity of C. sativa (4) due to
THC, which is present in the C. sativa’s dried leaves, seeds, stems,
flowers (sensimilla), and oil (5). The pot of the 1960s–1970s con-
tained 1–2% THC, while the Hawaiian sensimilla product was
3%; this is in contrast to current versions with much higher THC
percentage as measured by the Potency Monitoring Project and
other research (5, 6). A recent survey in Japan revealed an aver-
age potency of 11.2% with a maximum potency of 22.6% (7).
High-potency cannabis is referred to as “skunk.”
Cannabis remains a popular global drug that is easily obtained
around the world. Movements are increasing to legalize this drug,
because of the research noting positive medical benefits as well as
the intense euphoria it produces along with a popular, though false
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impression that this is a“safe”drug (8, 9). Cannabis remains a con-
troversial drug, because its illegal status places it in conflict with
the popular notion that pot is a harmless chemical – a notion made
fashionable or trendy by many media and Hollywood personali-
ties who may promote its use to enhance their joie de vivre. Such
promotions seem to be effective as noted by the popularity of this
illicit drug. However, marijuana (cannabis) has been prohibited
in the United States since the 1937 Marijuana Tax Act as a federal
law and is classified by the US Drug Enforcement Agency (DEA)
as an illegal Schedule I drug. Some states in the US have legal-
ized small amounts of cannabis that a person can carry without
forensic consequences.
PREVALENCE
Prevalence data for cannabis can be determined in various ways
such as self-report data, waste water (sewage) analysis, and sales of
cigarette paper (10, 11). Research notes that marijuana is the most
commonly used illicit drug on earth (12, 13). The most frequently
used substances among American adolescents are tobacco, alcohol,
and marijuana. Marijuana (“weed, pot, hash, BC Bud, Ganja, grass,
smoke, doobs,” others) is an illicit schedule I drug that constitutes
about three-fourths of the illegal drug utilization in the United
States (14–16).
Many studies have been done to confirm the high use of
cannabis among adolescents and young adults of the world. The
2007 European School Survey Project on Alcohol and other Drugs
(ESPAD) reported that life-time use of cannabis among students
(age 15–16 years) in Europe ranged from 3% in Armenia to 45%
in the Czech Republic with an average of 19% among 35 countries
(see Table 1). One-third of Canadian university students used
cannabis (17).
The United States Centers for Disease and Prevention (CDC)
YRBS (Youth Risk Behavioral Surveillance) reported a life-time use
(once or more times) among US high school students of 31.3%
in 1991 that increased to 47.2% in 1999 and was 36.8% in 2009
(19). Use of marijuana by US high schools students that occurred
30 days before the survey ranged from 14.7% in 1991 to 26.7%
in 1999 and 20.8% in 2009. Other studies note marijuana use by
adolescents that range from 28% in New York City versus 38%
across the United States (20). Prevalence of cannabis use disorders
have increased in veterans in the United States and were higher in
states which allowed cannabis for medical purposes (21).
CONSUMPTION OF CANNABIS (MARIJUANA)
Marijuana is typically smoked as a joint, but can be taken orally in
various foods, teas, or capsules which may be used as “medicinal”
marijuana. It can be prepared in food for oral consumptions, as
in brownies, cookies, or spaghetti. Various oral consumptions are
found in different countries. For example, in eastern Iran, there is
a special solid “pie” called Majoon Birjandi, which is consumed by
adolescents to reach a cannabis-induced euphoria (22).
The marijuana (bhang) cigarette is rolled from the C sativa
plant (upper leaves, tops, and stems) that is cut and dried. Hashish
refers to dried exudate that comes from the top and underside
of the plant leaves while concentrated hashish distillate is called
hashish oil. Sensimilla is another potent marihuana product that
is made from the seedless female flower of the cannabis plant. The
Table 1 | Life-time use of marijuana: 2007 ESPAD (18) (15–16 year olds).
%
Armenia 3
Austria 17
Belgium (Flanders) 24
Bulgaria 22
Croatia 18
Cyrus 5
Czech Republic 45
Estonia 26
Faroe Islands 6
Finland 8
France 31
Germany 20
Greece 6
Hungary 13
Iceland 9
Ireland 20
Isle of Man 34
Italy 23
Latvia 18
Lithuania 18
Malta 13
Monaco 28
Netherlands 28
Norway 6
Poland 16
Portugal 13
Romania 4
Russia 19
Slovak Republic 32
Slovenia 22
Sweden 7
Switzerland 33
Ukraine 14
United Kingdom 29
Average 19
“typical” marijuana cigarette includes about 20 mg of THC that
is produced from a gram of C sativa leaves and buds; however,
much variation in potency can be found (vida supra). THC can
be found in the body for up to 2 weeks after use of a single pot
cigarette. A blunt is a cigarette or cigar form made from tobacco
and filled with marijuana in a process called boosting ; this can be
used to boost the effects of other drugs such as alcohol (23).
CANNABIS AND OTHER DRUG USE
Pot is often combined with consumption of alcohol or diazepam
which increases cannabis sedative effects. Addition of various other
drugs enhances the euphoric effects. For example, marijuana is
often mixed with various drugs such as nicotine, cocaine, opioids,
or hallucinogens [as lysergic acid diethylamide (LSD)]. It is also
mixed with drugs such as phencyclidine (PCP) in which the joint
is dipped (hand-rolled) into PCP dissolved in an organic solvent
(as formaldehyde); after drying it is smoked – called “water, wet,
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or Sherms.” Such additions add to the complications of pot use.
Other additives include glutethimide and methaqualone, which
have been popularized in the past. Persons abusing marijuana who
also take disulfiram due to alcohol abuse can develop increased
psychoactive effects of cannabis due to THC blockage by the
disulfiram (24).
Cannabis users also smoke tobacco and research claimed that
this occurs for a variety of reasons, including shared genetic factors,
the similar cue of smoking for both, and withdrawal symptoms
that are seen to some extent in both (25). One study of 467 adults
who regularly smoked both cannabis and tobacco found that
one-third started with cannabis-first, nearly half initiated tobacco
before cannabis, and most cannabis smokers who stopped tobacco
did so after taking up regular cannabis consumption (26).
As noted, those who consume marijuana also tend to use other
drugs and it may serve as a gateway drug from early experimen-
tation in adolescence to other drug use (27, 28). For example,
two different studies reported that 45% of college students who
illegally used prescription drugs also abused marijuana, while
24–57% also abused alcohol (29). Cannabis initiation usually
follows alcohol use though cannabis use can start before alco-
hol use and African-Americans (versus European-Americans)
have an increased risk for this cannabis-first trend (30). Other
research notes increased risk for cannabis-related problems
in African-American females versus European-Americans (30).
Some research identifies declining socioeconomic position from
childhood to adulthood as a risk factor for cannabis as well as
tobacco consumption (31).
Some researchers reported that patients seen in a pain clinic
were at increased risk for use of marijuana; for example, one study
of these patients with 21, 746 urine specimens found 13.0% inci-
dence of urine with cannabis (THC); also, 4.6% were positive for
cocaine and 1.07% were positive for methamphetamine. (32). A
case-crossover research design study noted that cannabis was a
trigger for onset of cocaine use even when genetic influences and
various environmental conditions were held constant (33).
CANNABINOIDS
Cannabis sativa contains over 60 cannabinoids as well as over
400 other chemicals including benzopyrene, a known carcino-
gen. Table 2 lists some of the known cannabinoids (34). The
cannabinoids of the C. sativa plant include cannabidiol (CBD),
cannabigerol (CBG), and cannabinol (CBN) which, in contrast
to THC, are not psychoactive. CBD may activate central nervous
system (CNS) limbic and paralimbic regions which can reduce
autonomic arousal and feelings of anxiety; this is in contrast to
THC which can be anxiogenic (35). CBG is found in higher
concentrations in hemp and has been used to lower intraocular
pressure.
Other research also notes that THC and CBD influence dif-
ferent CNS regions and thus, have different effects on cannabis
users (36). In addition to anxiolytic effects, CBD has been shown
to have anti-emetic, anti-inflammatory, and anti-psychotic effects
(37). There is no effect on vital signs (i.e., blood pressure, pulse,
body temperature), gastrointestinal transit, or psychological func-
tioning. Doses up to 1,500 mg per day as well as chronic use of
CBD have been reported as being well tolerated by humans (37).
Table 2 |Types of cannabinoids.
Endogenous cannabinoid agonists
2-AG (2-arachidonoyl glycerol)
Anandamide (arachidonoyl ethanolamide)
Cannabidiol (CBD)
Isomer of THC
Cannabinol (CBN)
Metabolite of THC
Cannabigerol (CBG)
Alpha-2-adrenergic receptor agonist
Tetrahydrocannabinolic ACID
THC biosynthetic precursor
Synthetic cannabinoid agonists
WIN 55,212-2
JWH-133
HU-210
CP-55940
There can be hepatic drug metabolism inhibition, reduced activi-
ties of some drug transporters (i.e., P-glycoprotein), and lowered
capacity of fertilization (37).
Euphoria is produced from effects of this lipophilic drug on
cannabinoid receptors (ECS: CB 1 and CB 2) in mesocortical
and limbic systems; THC also effects the striatum and lateral
prefrontal cortex (PFC). Cannabinoid receptors are also found
in the liver, gastrointestinal tract, skeletal tissue, and adipose tis-
sue. There are endogenous ligands for cannabinoid receptors (i.e.,
N -palmitoylethanolamide and anandamide) that act like neuro-
transmitters (27). Part of the complexity of the cannabis issue is
the presence of the endogenous endocannabinoid system and this
system is now reviewed.
ENDOCANNABINOID SYSTEM
The endocannabinoid system consists of CNS cannabinoid recep-
tors and their endogenous ligands; ligands (Latin: binding) refers
to triggering molecules that bind to a target protein site (38).
Endocannabinoids (endogenous cannabinoid receptor agonists)
include arachidonic acid derivatives: 2-AG (2-arachidonoyl glyc-
erol) and anandamide [arachidonoyl ethanolamide (AEA)] (see
Table 2) (39, 40). AEA and 2-AG are the two most researched endo-
cannabinoids. The complex effects of this system on emotional
and cognitive behavior may be strongly influenced by various
environmental factors (41).
The endocannabinoid system is identified both as a cause
of psychiatric disorders but also research suggests that proper
manipulation of this system may be pharmacologically useful in
management of some psychiatric disorders – such as depression,
anxiety, anorexia nervosa, and others (42). For example, CBD may
be beneficial in treatment of psychiatric disorders (42).
The endocannabinoid system is involved in processes of brain
reward that are related to drug abuse – as noted in animal
and human research; this includes cue-induced relapse of drug
abuse (43). This CNS system is involved in various functions
involving memory, emotions, movement, cell proliferation, and
other important cell functions (44). Key neuron classes that
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express high levels of CB1 receptors are GABAergic interneurons
in such CNS areas as the cerebral cortex, amygdala, and hip-
pocampus; these areas also contain cholecystokinin, an important
neuropeptide (45).
The cannabinoid CB (1) receptor (CB1R) is mainly found in
the CNS and the CB (2) receptor is expressed in immune system
cells and recent research has shown the importance of this recep-
tor, not only concerning the immune system; both receptors are
G-protein coupled receptors and are involved in adenylate cyclase
inhibition (46, 47). The CB1R is a G-protein coupled receptor that
is associated with most of the CNS endocannabinoid signaling
(48). CB1R, also known as CNR1 and CB2R, also known as CNR2
are of importance and future research will most likely show us new
information. It is widely found in the cerebellum, basal ganglia,
and limbic system; the hippocampus has the highest concentra-
tion of cannabinoid receptors. Cannabinoid receptors are found in
other tissues including the heart, lungs, endocrine glands, arteries,
immune system, sympathetic ganglia, gastrointestinal tract, and
reproductive tract (39).
The activation of CB1 receptors can inhibit amino acid and
monoamine neurotransmitter release. Certain lipid derivatives
[i.e., 2-arachidonoyl glycerol (2-AG) and anandamide (AEA)] can
function as endogenous ligands for CB 1 receptors and lead to
excitation in such areas as the cerebellum and hippocampus by
inhibition suppression (45). Most drugs of abuse alter brain lev-
els of endocannabinoids. Since blockade of this system can change
the reward behavior associated with some drugs of abuse, the CNS
endocannabinoid system is under active research to develop med-
ications that may be helpful in treatment of drug abuse – including
drug relapse (43). Cannabis as potential medication (“medicinal
marijuana”) is now considered.
USE OF MEDICAL CANNABIS
Conclusions regarding the “benign” or “malignant” effects of
cannabis use influence different countries’ policies regarding legal-
ization or criminalization of cannabis use (49). This is also com-
plicated by use of cannabis products in a “medicinal” manner and
thus, effects to find the most “appropriate” variety (varieties) of
cannabis that are available (50, 51). A plethora of medicinal ben-
efits have been identified with marijuana use over past centuries
(52–54) (see Table 3).
The concern over the addictive and psychomimetic qualities of
THC placed active research on potential medical benefits of this
plant on the backburner until recently (54). However, increased
understanding of the cannabinoid signaling system has led to
increased research on potential medicinal uses of cannabis (55);
this endocannabinoid system, for example, is being analyzed for
use in treatment of various neuropsychiatric diseases (44).
Studies are looking at potential benefits of cannabinoids (phy-
tocannabinoids) in management of neuropathic pain, hyperten-
sion, post-stroke neuroprotection, multiple sclerosis, epilepsy, can-
cer, and other disorders (56–63). Cancer research, for example,
has identified that cannabinoids can inhibit cancer growth, angio-
genesis, and metastasis (63). Cannabinoid-like anti-inflammatory
products may be useful as material for wound dressing due to anti-
inflammatory effects (64). CBD is under research as a new class of
anti-inflammatory bowel disease drug (65).
Table 3 | Potential benefits of cannabis based on research studies (see
text).
Remedy for inflammation
Remedy for pain (including chronic pain and neuropathic pain)
Remedy for diarrhea (as in Crohn’s disease)
Treatment for dystonia
Treatment for multiple sclerosis
Treatment for rheumatoid arthritis
Treatment for glaucoma
Treatment for emesis due to chemotherapy
Treatment for epilepsy
Improvement of anorexia in AIDS patients
Treatment for Huntington’s disease
Management of inflammatory bowel disease
Beneficial effect on atherosclerosis
Reduce brain infarct size
Block negative memories in posttraumatic stress disorder
Reduce cardiac reperfusion injury
Adjuvant treatment for prostate carcinoma
Others
A number of cannabis products are being manufactured
by pharmaceutical companies, including Sativex (THC+CBD),
Marinol (dronabinol; THC; Schedule III drug), and Cesamet
(THC, Schedule II) (54). The latter two have been approved for
use in the anorexia-cachexia syndrome as well as for nausea and
vomiting (54). Dronabinol is a synthesized gelatin capsule which
has been used to treat glaucoma by lowering intraocular pressure
or relieve chemotherapy-induced emesis (vida infra) (66). Mari-
juana has been used to treat the wasting syndrome associated with
HIV/AIDS (9). A newer tablet formulation of THC is Namisol
(>98% THC) which has been studied to ameliorate pain and
spasms in adults with multiple sclerosis as well as relieve nausea,
and emesis in HIV or cancer patients (67).
Though cannabis users noted lowering of anxiety and feelings
of anxiety, much research remains to be accomplished to iden-
tify which if any cannabinoid products may be therapeutically
and safely used as pharmacologic management of individuals with
anxiety disorders (68). Current research is looking at such anxiety
disorders as social anxiety disorder, posttraumatic stress disorders,
panic disorder, and obsessive-compulsive disorder (69, 70).
Research suggests that the phytocannabinoid chemical, CBD,
may be useful in blocking negative or fear memory associated
with posttraumatic stress disorder in a process called reconsolida-
tion blockage (71). Some research notes a lower mortality rate
among adults with schizophrenia and related psychotic disor-
ders in those who smoked cannabis versus those who did not
smoke cannabis (72), while research on smoked, vaporized, and
oral cannabis products for potential improvement of health are
continuing (73).
SYNTHETIC CANNABINOIDS (CANNABINOID DESIGNER DRUGS;
CANNABIMIMETICS)
A number of designer drugs have become available in the twenty-
first century and cannabis has become involved in this trend as
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well (see chapter 18). These synthetic cannabinoids (called “legal
highs,”“Spice drugs,”“K2” drugs) are similar to THC found in the
C. sativa plant and produce similar effects to smoking cannabis
since they bind to the same cannabinoid brain and peripheral
organ receptors as THC (74–80). These herbal blends have been
noted since 2008 in various“herbal”smoking products sold via the
internet and in retail outlets (called “head shops”) that focus on
drug paraphernalia sold for cannabis and other drug use; brand
names include such exotic names as Aroma, Yucatan Fire, Spice
Gold, and others (74, 81).
Though available in some countries, advertised as “safe,” (since
they do not resemble the chemical structure of THC) and con-
sidered legal in various locations, they are potentially dangerous
drugs – having up to 10 times the strength of delta-9-THC (75, 82,
83). In a moving and dangerous cat and mouse game,sellers change
the synthetic cannabinoids in attempts to avoid putting up for sale
a specific product identified as illegal in a specific country or area.
As one synthetic cannabinoid is banned, others are produced to
take their place as there are over 140 different Spice drugs that are
produced (74). They may be marked as some type of “incense” or
“herbal” product and even “air fresheners” but potential adverse
reactions remain (77, 78). Toxicology screens looking at THC may
miss the presence of these cannabinoid designer drugs (77, 79).
They are typically tobacco and cannabis free but produce sim-
ilar cannabis effects that can include withdrawal symptoms, anx-
iety, intoxication, psychosis, death, and others (vida infra) (74,
84). Some reports suggest that increased hallucinations and para-
noia are noted with these “spice” synthetic cannabinoids (79). Part
of the potential danger is that they can contain various added
but often unknown chemicals that are part of the manufacturing
process. However, some of the products found on the internet do
not have significant amounts of impurities and adverse effects are
due to the synthetic cannabinoids themselves and the potential
additives (85).
CANNABIS LAB TESTING
Those smoking 3.55% pot develop a peak plasma level near
160 mg/ml 10 min after beginning to ingest this product; the THC
is removed from the plasma to body tissues leading to its euphoric
effects and then to body fat as long-term storage (6). THC is then
eliminated over several weeks in the urine and feces. Urine tests
can be used to establish the presence of cannabinoid metabo-
lites and can be positive in casual users for up to 10 days versus
14–30 days for chronic pot users (27). Current drug testing (using
high-performance liquid chromatography with diode-array detec-
tion) can identify low THC content in cannabis seedlings right
after germination; however, chemotype determination of THC can
occur as the plant ages – at 3 weeks and beyond (86).
Cannabis testing can be used to verify past pot use but not the
presence of cannabis intoxication, dependence, or abuse. Testing
may also note suppression of testosterone and luteinizing hor-
mone (LH), though it is unclear what such tests actual mean from
a clinical viewpoint. Passive inhalation of cannabis does not result
in a positive urine test for THC. Urine testing for THC does not
identify the presence of synthetic cannabinoids.
Tetrahydrocannabinol-COOH (11-nor-9-carboxy-THC) is the
main secondary THC metabolite developed after cannabis is taken;
it is not psychoactive but has a long-half life and can be detected
for days and in heavy cannabis users, for weeks after consump-
tion. It is an important metabolite used in blood or urine testing
for identification of cannabis; urine THC-COOH testing has been
used to identify cannabis abstinence and a positive test can be con-
firmed with gas chromatography-mass spectrometry THC blood
testing that indicates recent cannabis exposure (6). Whole blood
and plasma testing can also reveal 11-hydroxy-THC after smok-
ing cannabis. Polymerase chain reaction (PCR) testing is available
to police to identify where specific C sativa samples came from
in order to assist with forensic studies and investigations (87). In
addition to urine as well as blood testing, saliva and hair testing
for cannabis are possible – the latter for evaluation of chronic
cannabis exposure (88, 89).
MEDICAL ADVERSE EFFECTS
Though some authors question the data on negative effects of
cannabis use, most authors conclude that use of cannabis has
significant risks for the user in a dose-dependent and/or idio-
syncratic fashion (90, 91). Identifying adverse effects of cannabis
is challenging because studying an illicit drug can be problematic
as can separating out cannabis effects from other drugs that are
often taken simultaneously, such as tobacco or alcohol; also, there
is variation in techniques of cannabis consumption (90, 92–94).
A case of an infant with altered consciousness after exposure
to cannabis smoke (passive inhalation) has been reported (95).
Another 10-month-old infant consumed oral cannabis and pre-
sented with cannabis poisoning – drowsiness, generalized hypo-
tonia, and restlessness; this infant had high blood as well as urine
levels of cannabis products and recovered with symptomatic man-
agement that included clinical monitoring for the first 24 h after
the ingestion (96).
A number of side effects are possible for the cannabis consumer
including increased mortality rates (see Table 4). Chronic use can
lead to weight gain from overeating and reduced physical activ-
ity. Acute pot use can lead to suppression of rapid eye movement
(REM) and diffuse slowing of background EEG activity (27). The
smoke of cannabis can be irritating to conjunctival, nasopharyn-
geal, and bronchial tissue leading to injected conjunctiva, chronic
cough, sinusitis, pharyngitis, and (chronic) bronchitis (97). Ado-
lescents or young adults who present with chronic cough should be
screened for cannabis use in addition to more classic causes, such as
asthma, gastroesophageal reflux, respiratory tract infections, and
others (98, 99).
Chronic use of cannabis has not been shown to effect thy-
roid function (100). Acute pancreatitis linked to cannabis use has
been reported in a 22-year old male who presented with epigas-
tric pain, nausea, and emesis (101). Abdominal pain due to colonic
perforation and subsequent peritonitis has been reported as a com-
plication of cannabis body packing in attempts to illegally smuggle
illicit drugs from one country to another (102).
CANNABIS HYPEREMESIS
Cannabinoid hyperemesis is noted in some cannabis users who
present with usually sudden, severe, and cyclic (intractable) emesis
which resolves with intravenous fluids, antiemetics, and cannabis
cessation. There can be cyclic nausea and abdominal pain as well
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Table 4 | Potential adverse effects of marijuanaa (see text).
Addiction (physiologic)
Withdrawal syndrome
Dependence (psychological) and with heavy use, tolerance
Variety of negative psychological reactions: anxiety, hallucinations, violent
behavior, depression, fear
Overt precipitation of psychosis or depression
Insomnia (can be chronic and improved with trazodone)
Memory spans that are impaired
Blunted reflexes
Flu-like reaction (after stopping this drug after 24–60 h, lasting up to
2 weeks)
Confusion and cognition impairment
Alteration of time perception
Amotivational syndrome (lose interest in school or work success)
Physiologic responses can include cough, bronchospasm, bronchitis
Amenorrhea
Immunologic dysfunction
aUsed with permission from Ref. (14).
and after a careful evaluation, the cause is linked to cannabis
use (103). It was first described in Australia in 2004 and may
be missed in patients presenting with hyperemesis and abnormal
patterns of bathing (104). Though cannabinoids have been used
to treat chronic nausea and emesis, a paradoxical effect on the gas-
trointestinal tract in noted in cannabis hyperemesis syndrome and
three parts are described: prodromal, hyperemetic, and recovery
phases (105).
The hyperemesis phase is usually resolved in 48 h. Patients
may report temporary symptomatic improvement with prolonged
hot showers or bath exposure and thus, compulsive hot water
bathing has become part of the cannabis (cannabinoid) hypereme-
sis complex (103, 106–108). Diagnostic confusion with the cyclic
vomiting syndrome may occur (105). If cannabis use resumes, the
hyperemesis complex may recur (105, 106, 109).
DENTAL EFFECTS OF CANNABIS
Pot users tend to have increased risks for dental caries, oral infec-
tions, and periodontal disease (110–112). Dysplastic changes and
premalignant lesions can be identified in oral mucosa of cannabis
users (110). Use of local anesthetics in patients intoxicated with
cannabis intensifies and prolongs pot-induced tachycardia (110).
Exposure to smoking (cannabis or tobacco) leads to contact
with many carcinogens (pro-carcinogens) such as polycyclic aro-
matic hydrocarbons (113). Cannabis users often smoke tobacco
and drink alcohol which increases carcinogen exposure and risk of
oral squamous cell carcinoma which represent 95% of malignant
lesions in the mouth (113).
PULMONARY EFFECTS
Some research identifies an anti-inflammatory effect from con-
sumption of the C. sativa plant. For example, one study of
5,115 adult males that took place over 20 years noted that occa-
sional and low cumulative cannabis use was not associated with
adverse effects on pulmonary function (114). Murine studies sug-
gest that CBD has an immunosuppressive and anti-inflammatory
effect on acute lung injury because of an increase in extracellular
adenosine (115).
However, it is known that marijuana, as well as tobacco, con-
tains a toxic combination of gases and other substances that can
be injurious to the pulmonary system (116). Marijuana smokers
usually smoke fewer “joints” than tobacco smokers consume cig-
arettes; however, methods of cannabis smoking may place more
cannabis particulate matter into the lungs than noted with typ-
ical cigarette smoking. (116). Those with cannabis dependence
will continue to use it despite chronic cough, excessive sedation,
or other marijuana-related problems. Combining marijuana with
tobacco leads to known tobacco-effects via second-hand smoke.
Pot use can induce some bronchodilation but regular or heavy
cannabis consumption can result in generalized airway inflamma-
tion with evidence of respiratory epithelial cell injury and damage
to alveolar macrophages which can lead to pulmonary infection
(116). Sharing of cannabis water pipes has led to the develop-
ment of pulmonary tuberculosis (TB) (117). Smoking cannabis
that contains fungal spores can result in pulmonary aspergillosis
in those with immune-compromised conditions (117, 118).
There is a dose-related large airway dysfunction with hyper-
inflation and obstruction of airflow; one cannabis joint has
been noted to be equivalent to 2.5–5 cigarettes in terms of this
pulmonary dysfunction (119). Macrophage injury can result in
cytokine and nitric oxide impairment. Smokers of cannabis are
typically exposed to more carbon monoxide and tar than cigarette
smokers; this effect is not related to the THC content (120).
Heavy and/or chronic users of cannabis may have persistent
cough, bronchitis (bullous) emphysema [chronic obstructive lung
disease (COPD)], pulmonary dysplasia, pneumothorax, TB, and
other respiratory infections (27, 116, 117, 121). Cannabis can
lead to increased airway resistance and large airway inflamma-
tion though causal links to COPD or macroscopic emphysema
remain controversial and unproven (93, 94, 119, 122). Smok-
ing both tobacco and marijuana increases risks for abnormal
tracheobronchial histopathology and COPD (122).
CANNABIS AND CANCER
Marijuana smoke contains toxic chemicals in amounts similar to
or higher than that found in tobacco and is linked as a potential
respiratory tract carcinogen (27, 94, 97, 121). Chronic inflam-
matory and precancerous airway changes in a dose-dependent
relationship as well as increase in airway cancer are reported in
cannabis users (91). Anecdotal reports of upper and lower respi-
ratory airway cancer have been published (117, 123). For example,
a case of small-cell lung cancer was reported in a 22-year-old male
who smoked one marijuana joint three times a week for 3 years
(124). However, specific link of cannabis to lung cancer remains
unproven (93, 94, 125). Current literature suggests that cannabis-
only smokers are at lower risk of lung cancer than tobacco-only
smokers (126). However, some epidemiologic data does place an
independent role of cannabis smoking in the development of lung
cancer (127, 128).
CARDIOVASCULAR EFFECTS
Cannabinoids have complex and varying effects on blood pressure
depending on which cannabinoid is being studied (34). Acute
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effects of cannabis include increase in heart rate along with an
increase (usually mild) in blood pressure and then decreased
vascular resistance-induced orthostatic hypotension (56, 129).
Individuals with coronary heart disease may have increased cardio-
vascular adverse effects from cannabis use (90). Cannabis-induced
ST segment elevation mimicking the Brugada syndrome has been
reported (130,131). Other drugs,both licit and illicit (i.e., cocaine),
have been linked with the Brugada syndrome as well (132).
Reported cardiovascular effects linked to cannabis include
anecdotal cases of acute coronary syndrome, congestive heart fail-
ure, and arrhythmias (56, 97, 130, 133–136). Patients with angina
may have decreased time with chest pain onset due to the acute
effects of cannabis use; also, myocardial infarction may be trig-
gered by the acute effects of cannabis use (56). Patients at high
risk for coronary heart disease should be advised to avoid using
cannabis (56).
Studies on cannabis also provide evidence of positive or “neu-
tral” effects from cannabis consumption. For example, though
inhalation of marijuana may induce acute coronary symptoms,
ingestion of cannabinoids may have a positive effect on ather-
osclerotic heart disease via effects on the endocannabinoid sys-
tem (135). Also, cannabis use has not been specifically linked
to increased hospitalization due to cardiovascular disease or
increased mortality from cardiovascular etiology (56). If a patient
has a cardiac death and has a positive urine test for cannabinoid,
a plasma THC level should also be done before seeking to link the
cannabis history with the cardiac death.
MOTOR VEHICLE ACCIDENTS
Adolescents and young adults who drive vehicles under the influ-
ence of pot (often combined with alcohol) are at increased risk
(two-times) of motor vehicle accidents leading to potential death
and injury (90, 91, 97, 137, 138). Those who consume cannabis
without other drugs also place themselves at increased risk for
motor vehicle crashes (138). Individuals driving under marijuana
influence may experience distortion of on-coming vehicle head-
lights resulting in motor vehicle crashes. Driving impairment
worsens with increasing amounts of cannabis consumed (139).
The problem of driving while under cannabis influence is increas-
ing and in some areas of California, for example, the rate of
nighttime weekend drivers who tested positive for THC was nearly
20% (140). Unfortunately, tests used in the field to identify if
cannabis is involved in motor vehicle accidents may not be sensitive
enough to detect the precise presence of this drug (141). Cannabis
consumption is also involved in non-traffic injuries, especially falls
in the older adult population (142).
SPORTS DOPING
Those involved in sports should understand that cannabis is a
drug banned by the World Anti-Doping Agency despite history
of pot use in the Olympics and it has been on the list of prohib-
ited drugs of the International Olympic Committee since 1989
(76, 143). Cannabis smoking results in reduced exercise test dura-
tion during maximal exercising and increased heart rate at less
than maximal exercise levels (56). Cannabis-induced increase in
blood pressure and reduced psychomotor activity can also decrease
overall athletic performance. Management of urine samples from
athletes can be problematic because of the intricacies of interpret-
ing urine samples due to the complexities of prolonged cannabis
excretion (144).
ADVERSE EFFECTS: PSYCHIATRIC
CANNABIS AND NEURODEVELOPMENT EFFECTS
Adverse neuropsychological effects of cannabis use must be sepa-
rated out from the acute effects of cannabinoids, effects of heavy
cannabis consumption, and psychiatric disorders worsened or
even caused by cannabinoids (145). Specific effects in individual
cannabis users are difficult to predict because of the heterogene-
ity or non-uniformity of different studies that have been done
to seek neuroimaging effects in cannabis use; some authors have
concluded it is difficult to prove major effects of cannabis on
brain structure (146, 147). Some research suggests that identified
cannabis-related neurocognitive performance defects disappear
after 25 days of cannabis abstinence (148).
However, other recent research studies are noting that cannabis
users demonstrate important deficits in prospective memory and
executive functioning that exist beyond acute cannabis intoxi-
cation (149). The presence of cannabis and nicotine use disor-
ders in parents appears to increase the risk for major depres-
sive disorder in their late adolescent offspring (150). Studies in
animals and humans suggest a subtle (versus gross) effect on
cognitive functioning with later development of hyperactivity,
reduced attention span, impulsivity, depression, and substance
use disorders (151). Most frequently reported adverse effects of
cannabis use include mental slowness, reduced reaction times,
and increased anxiety (90). Dysfunction occurs to dopamine and
opioid neurotransmitter systems (152).
Animal and human research concludes that the developing
brain, with its high neuronal plasticity, is vulnerable to exposure
to exogenous cannabinoids, particularly in the perinatal/prenatal
period and during young adolescence (44, 152–155). Animal and
human studies suggest that early onset of cannabis use (i.e., early
adolescence) can increase risks for cognition dysfunction, CNS
changes (i.e., low striatal dopamine release), neuropsychiatric dis-
orders, cannabis dependence,and consumption of additional illicit
drugs (153, 156). Persistent or problematic marijuana use can lead
to major interference with daily life activities whether at work, in
school, or in one’s home.
Cannabis use often develops in adolescence and early adult-
hood which, as noted, is a vulnerable time for subsequent adverse
brain effects (48). For example, cannabinoid receptors are abun-
dant in the CNS white matter in adolescence as well as young
adulthood; long-term cannabis use during this time period can
lead to impaired axonal fiber connectivity with negative effects on
the white matter of the brain (157). Cannabis use in early ado-
lescence may alter CB1R signaling with potentially increased risk
for development of psychiatric disorders (48). Early adolescent
cannabis use has been linked with adolescent drop-out behavior
in some research (158).
Some research links other CNS problems with heavy cannabis
use. For example, one study identified regional brain abnormali-
ties (in the hippocampus and amygdale) in long-term, heavy pot
users – data found in both human and animal studies (159). Ani-
mal studies noted hippocampal-dependent short-term memory
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deficits that occurred in some but not all rats given chronic
cannabinoid administration (160).
CANNABIS AND ADHD
One report of 162 adolescents studied during inpatient manage-
ment of problems related to drug dependence (i.e., marijuana,
heroin, alcohol, or cocaine abuse) revealed attention deficit hyper-
activity disorder (ADHD) in 34% of them (161). A study from
different medical centers that focused on 600 adolescents (ages 13–
16 years of age) who were undergoing management for marijuana-
related problems reported that 38% also had ADHD (162). Such
studies support the theory that ADHD and adolescent substance
abuse disorder (including cannabis dependence) can be seen as
a developmental disorder with similar underlying physiologic
mechanisms (20).
CANNABIS DEPENDENCE
Psychological dependency and tolerance are classically described
in pot smokers. The American Psychiatric Association’s DSM-IV-
TR describes two cannabis use disorders (cannabis dependence
and abuse) and six categories of cannabis-induced disorders (see
Table 5) (27), while DSM-V has included cannabis withdrawal.
Some have placed the dependence rate at 7–10% of regular users
(91), while a susceptibility gene, NRG1, has been associated with
cannabis dependence in African Americans (163).
Those with cannabis dependence can consume cannabis in
potent forms for years and spend several hours a day in find-
ing as well as taking it; there can be physiologic dependence and
also psychologic dependence (27). Cannabis intoxication may last
longer with oral cannabis versus smoking it. Intoxication may even
last up to 24 h due to effects of enterohepatic circulation and/or
slow release of fat soluble THC and other cannabinoids from
fatty tissue. Cannabis use disorders are more common in males
versus females and are most prevalent in the 18- to 30-year-old
group (27).
Depersonalization and derealization episodes are described in
pot users (27). Anecdotal cases of cannabis-induced deperson-
alization in adolescents have been reported (164). A history of
conduct disorder in childhood or adolescence and antisocial per-
sonality disorder are risk factors for substance use disorder includ-
ing cannabis-related disorders (27). Differentiation of cannabis-
induced disorders from primary mental health disorders can be
difficult. Ataxia and aggression are more likely to be seen with
Table 5 | DSM-IV-TR cannabis use and induced disorders (27).
Cannabis use disorders
Cannabis dependence
Cannabis abuse
Cannabis-induced disorders
Cannabis intoxication
Cannabis intoxication delirium
Cannabis-induced psychotic disorder, with delusions
Cannabis-induced psychotic disorder, with hallucinations
Cannabis-induced anxiety disorder
Cannabis-related disorder not otherwise specified
phencyclidine (PCP) intoxication versus cannabis intoxication;
aggression with nystagmus or ataxia is more likely to be from
alcohol intoxication (27).
Demonstrating a direct link between cannabis use and the
development of overt depression has been problematic and not
clearly proven (165). Regular cannabis consumption (particularly
daily use) in adolescence has been linked with increased risks for
anxiety disorders in adolescents and young adults, even after the
cannabis was stopped (155). Anxiety is linked to regular or heavy
use of cannabis and further research is needed to unravel this con-
nection in more detail (166). For example anxiety can arise due to
fear of being discovered by law enforcement officials; there can be
episodes resembling panic attacks.
CANNABIS WITHDRAWAL SYNDROME
Chronic pot users can develop psychological addiction and a
withdrawal syndrome comparable to heroin addiction (8). A
heavy marijuana user, whether an adolescent or adult, who sud-
denly stops this drug can develop a recognizable withdrawal
syndrome as reported by various research studies (167–173).
Withdrawal symptoms can develop within 48 h of cessation and
include irritability, restlessness, anxiety, aggression, and sleep
difficulties. (90). Withdrawal symptoms tend to subside in 2–
12 weeks after cannabis abstention (90). As noted, a CNR1 gene
has been linked with abstinence-induced withdrawal symptoms
(174). Heavy cannabis use has been linked with a smaller amyg-
dala and hippocampus while those with CNR1 may be predis-
posed to smaller hippocampal volume following heavy cannabis
use (174). Some smoke pot to control problems with anger
(170–173).
Withdrawal symptoms are due to the cessation of THC and are
relieved with taking delta-9-THC or simply smoking marijuana
(167, 175). Adolescents undergoing treatment for cannabis depen-
dence experience withdrawal symptoms most acutely during the
first week of cannabis absence and this tends to ease over the next
month of abstinence (167, 176). Research notes that the majority
of heavy pot users report several symptoms after stopping cannabis
and this can complicate effective management, especially since
cannabis-dependent users may resort to consuming various others
drugs to relieve the symptoms of cannabis withdrawal (167, 177).
Diagnostic criteria for a formal cannabis withdrawal syndrome
(CWS) have been included in the fifth edition of the American Psy-
chiatric Association’s Diagnostic and Statistical Manual of Mental
Disorders (DSM-V) (178).
ADDICTION
The identification and isolation of THC in 1964 enhanced spe-
cific research into effects of cannabis on humans and animals
(44). Endogenous cannabinoids (particularly CB1 receptor acti-
vation) activate neural mechanisms in the CNS similar to how
other reward-enhancing drugs induce drug addiction (179–181).
This core reward system is part of the addiction mechanism that
use of cannabis develops in the unwary pot smoker as well as in
users of other illicit drugs of addiction (182, 183). This mecha-
nism involves the meso-accumbens reward circuitry of the CNS
as well as neural firing of the neurotransmitter, dopamine. Some
research notes that THC can induce striatal effects on dopamine as
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noted with other drugs of abuse (184). Though some studies sug-
gest dependence develops faster in cocaine versus cannabis users,
recent research concludes there is no such difference (185).
Addiction also involves PFC dysfunction with frontostriatal
dysfunction and the erosion of the ability to stop the addiction;
more research is needed to identify potential impact of cannabi-
noids in the PFC and its potential role in cannabis dependence
(186–188). A nucleotide polymorphism has been identified in a
cannabis receptor-1 gene (CNR1) – rs2023239 – that is associ-
ated with cannabis dependence, cannabis craving, and withdrawal
symptoms due to cannabis abstinence (174). Some neuropeptides
called orexins (hypocretins) originate in the lateral hypothala-
mus and are linked to features of drug addiction (i.e., cannabis,
nicotine) that include drug craving, relapse, and withdrawal (189).
CANNABIS AND PSYCHOSIS
Chronic use of cannabis, particularly with the newer synthetic
cannabis products, is associated with increased rates of psychosis
(190–192). Frequent cannabis use increases the risk by two times
for schizophrenia and psychotic symptoms, perhaps by cannabis-
induced disruption of the endocannabinoid system in which the
normal signaling and functioning of this endogenous system is dis-
turbed (193). Cannabis (marijuana) is commonly used by those
with schizophrenia and can cause paranoia in approximately 40%
of persons experimenting with this drug (194). Patients with schiz-
ophrenia who consume cannabis are hospitalized at rates higher
than those who do not use cannabis (195).
Cannabis-induced schizophrenia is currently theorized as being
due to dysfunction of late postnatal brain maturation in which
glutamatergic transmission dysfunction leads to abnormal pre-
frontal neurocircuitry (196). Exposure of adolescents to cannabis
at certain times in adolescence and at certain doses may lead to pre-
frontal cortical circuitry abnormalities with the result of inducing
schizophrenia in susceptible adolescents (196).
One research group reports a mean time of 7.0± 4.3 years
between onset of cannabis use and onset of psychosis (191). Those
at risk for psychosis may be vulnerable to brain volume loss (i.e.,
cerebellum, PFC, and cingulate) due to use of cannabis (197). Self-
mutilation can also occur with cannabis-induced psychosis (198).
Those with psychosis who use cannabis may not notice improved
psychotic symptoms with cessation of their cannabis (199).
Most cannabis users do not develop psychosis and
this cannabis-psychosis link appears to be via a complex
environmental-genetic-molecular interaction possibly involving
anandamide dysfunction and other biological factors (192, 200,
201). Most research suggests a link between cannabis use and
risk for suicide in patients with psychosis and also those with-
out psychosis (202). The development of schizophrenia and use
of cannabis share a variety of similarities, including neuropsycho-
logical deficits, reduced motivation, hallucinations, and initiation
in late adolescence (203).
Cannabis is also a very common illicit drug for individuals
with psychosis and disruptive disorders to consume (13, 204).
Those with psychosis have a higher rate of cannabis use than the
general population, probably in attempts to utilize the cannabis-
induced euphoria to deal with negative aspects of schizophrenia,
such as boredom and depression (12). Cannabis can also prompt
the onset of psychotic symptoms in otherwise healthy people as
well, and this includes paranoia and/or delusional thinking due to
effects of THC on striatal and prefrontal function.
Thus, use of marijuana can have opposite effects on different
users. Some research fails to find a clear association between use of
cannabis and symptoms of psychosis, especially with low or mod-
erate cannabis use (205). A major component of cannabis, CBD,
has been shown by some research to have anti-psychotic effects
(206). The presence of CBD may explain the lack of psychosis
development in many cannabis users. Studies with CBD (versus
THC) suggest a modulating effect based on functional MRI brain
imaging (207). Schizophrenic patients using cannabis may be par-
ticularly sensitive to brain damage from the cannabis though CBD
may provide a protective effect from brain volume loss (203).
MANAGEMENT
BEHAVIORAL THERAPIES
The “hedonic” CNS dysregulation seen in drug addiction studies
in animals and human subjects underscores the concept of drug
addiction as a brain disease and the necessity of prevention before
this complex brain dysfunction arises (12, 183, 208). Indeed, it is
difficult to convince an addicted cannabis user to stop smoking
this plant and thus, prevention via intensive and comprehensive
education is the best option currently available. Unfortunately
cannabis dependence is difficult to treat successfully and few who
seek to stop their cannabis addiction succeed in long-term ces-
sation (181). One of the ironic reasons for this is that chronic
cannabis consumers classically have cognitive impairments which
lead to defects in their decision making skills (209).
However, there are steps therapists can take in helping this phe-
nomenon of a nation and a world obsessed with smoking pot.
Continued education of the dangers of cannabis should take place
on a persistent and relentless basis. It should be understood that
some literature and some people conclude that the negative impact
of smoking cannabis is limited (210). Cannabis consumers may be
cognizant of such literature, which may encourage them to con-
tinue to use this so-called safe illicit drug. Thus, teaching about
the potential problems of cannabis should always be provided
by healthcare providers to help offset this destructive message of
“benign” pot consumption.
Treatment specifically for cannabis use is needed as manage-
ment of other or co-existing drug dependence (such as heroin,
tobacco, or alcohol, for example) does not necessarily reduce lev-
els of cannabis consumption (211). Comprehensive school-based
prevention programs teaching about drug use, including cannabis,
can be beneficial in lowering youth drug experimentation and
addiction (212, 213). Increased education about high-risk adoles-
cent behaviors for adolescents and their parents can be useful in
prevention efforts (214). Intense education is needed for groups
at high risk for drug abuse, such as males, young adults, and
individuals with increased psychological stress (215).
Behavioral principles for management in adolescence can be
directed by factors shown to suggest higher risk for cannabis use
including genetic factors, family history, minimal parental super-
vision, drug availability, high-risk peer group, and those with a
need for higher thrill-seeking activities (216, 217). Groups at high
risk of mental health problems are those with combined drug
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use, such as comorbid cannabis and methamphetamine; thus, this
group should receive intense management (218). Comprehensive
behavioral management can also be of help in reducing cannabis
use in those arrested for cannabis possession (219). Screening of
these persons for suicide risk is recommended and lower cannabis
use can reduce risks for suicide in those with and without psy-
chosis (202). Patients with psychosis and cannabis smoking should
undergo behavioral therapies to improve both problems and not
just one (220).
If life-time abstinence from cannabis is not possible, delaying
its use (especially heavy use) as long as possible after adolescence
and young adulthood, may result in less white matter damage
from cannabis consumption than noted during cannabis smok-
ing in the second and third decade of life (157). Management can
also focus on reducing cannabis use if abstinence is not possi-
ble, since adverse effects tend to be increased with heavy use of
cannabis (92). Therapy should seek underlying factors in use of
cannabis or other drugs. For example, research notes that socially
anxious males are at increased risk for use of cannabis as part
of a mechanism to deal with or avoid social situations (221).
Thus, therapy can be directed at reasons for this avoidance behav-
ior and the acquisition of successful strategies to improve their
social anxiety which may reduce the need for ongoing cannabis
consumption.
Often recommended behavioral management strategies (such
as cognitive-behavioral therapy and contingency management)
have their limitations and combination of these techniques does
not increase success in helping those with cannabis dependence
(222). However, research notes that youth with cannabis use dis-
order benefit more from CBT (versus family therapy) if they are
older teenagers (i.e., 17–18 years of age) and do not have pre-
existing psychiatric disorders; in the same study, multidimensional
family therapy was more helpful (versus CBT) for those who
were younger (i.e., under age 17) and/or had a past year his-
tory of disruptive disorders (i.e., opposition defiant or conduct
disorder) (223).
However, one should continue to provide the cannabis con-
sumer with hope and encouragement that overcoming this drug
addiction is possible despite its wide acceptance in society.
Research does show that such benefit is more likely with intensive
or prolonged behavioral therapy, especially cognitive-behavioral
therapy and motivational interviewing (224). Also, it should be
understood that even brief (i.e., four) sessions of motivational
interviewing with cognitive-behavioral therapy delivered via tele-
phone can be beneficial, at least in the short run, for motivated
cannabis users who called in seeking help with treatment (225).
Behavioral therapies can be useful in the motivated cannabis
addict and such counseling seeks to help the cannabis consumer
gain control over their addiction at the CNS level by enhanc-
ing neuroanatomical progression from ventral striatal (nucleus
accumbens) to dorsal striatal control (183). Even brief interven-
tions may have positive benefit in less cannabis use at 3 month
follow-up (3) and another study at 12-month follow-up (17).
Also, therapy seeks to help the addict deal with cannabis craving
and relapse triggers, such as becoming re-exposed to various drugs
of addiction; it is also important to help this person deal with stress
and also with finding and avoiding old clues in his/her milieu,
such as key persons, places, or objects (183, 208). Genetic factors
also have a role in why some develop addiction and are recal-
citrant to management strategies (208). Involvement of families,
schools, communities, and peer groups are critical in seeking to
reduce and prevent cannabis smoking in adolescents. It is unclear
what the interactions are between abuse of illicit drugs and use of
prescription drugs, but the potential drug interactions should be
considered in prevention and treatment plans (226).
PHARMACOLOGIC THERAPIES
There are currently no FDA-approved pharmacologic agents for
management of cannabis dependence. Traditionally, pharmaco-
logic agents have not been specifically beneficial in treating mar-
ijuana addiction whether dependence or withdrawal symptoms
(227). However, a careful assessment of each patient is necessary
and a reduction in cannabis use can be noted in some patients
under standard pharmacotherapy for mental illness (224). There is
no evidence that one anti-depressant, anxiolytic, or anti-psychotic
is more effective than another. Cannabis use disorders are com-
mon in those with schizophrenic spectrum disorders; however,
there is no current literature that guides clinicians in the best
treatment approaches for this dual diagnosis (228). Knowledge,
however, is slowly emerging to guide pharmacologic therapies for
cannabis-induced problems in the twenty-first century.
Individuals with co-occurrence of cannabis and tobacco use
tend to have higher abstinence rates if treatment includes measures
aimed at dual abstinence (25). Thus,pharmacotherapy for nicotine
addiction may help the individual stop marijuana use as well by
removing use of and thus, influence of tobacco. Pot-associated per-
sistent insomnia may be improved with use of trazodone. Research
is looking at new methods of treatment that will emerge from the
study of the genetics of addiction including gene-milieu interplay
and role of genetic variation (229).
CANNABIS INTOXICATION
Pharmacologic management typically centers on use of benzodi-
azepines or atypical anti-psychotics. Propranolol and rimonabant
(vida infra) have been reported to be beneficial in manage-
ment of acute, physiologic effects of cannabis intoxication; use
of flumazenil and CBD is under current study in this regard (230).
CANNABIS WITHDRAWAL
Oral THC (dronabinol) may relieve cannabis withdrawal symp-
toms but not relapse (231, 232). Adding dronabinol and lofexi-
dine (alpha-adrenergic receptor agonist) can lower the severity of
withdrawal and lower relapse rates in those with cannabis depen-
dence (233). The anti-depressant mirtazapine can also help those
undergoing cannabis withdrawal.
CANNABIS-ASSOCIATED PSYCHOSIS
Cannabidiol has been shown in animal and human studies to have
anti-psychotic effects and it may become a useful pharmacother-
apeutic agent for schizophrenia management (206). Research has
therapeutically targeted the cannabinoid (CB1) receptor since
delta-9-THC is a partial CB1 receptor agonist. Treatment of
patients with psychotic disorders and cannabis use should include
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seeking to reduce or stop the cannabis use, perhaps using cannabi-
noid agonist medication (220). Those with psychosis can be
provided with appropriate anti-psychotic medications.
CANNABIS DEPENDENCE
Nabilone is a synthetic THC analog with improved bioavailability
over dronabinol and is under current research as a potential med-
ication for marijuana dependence as it may lead to a positive mood
and limited adverse cognitive effects in marijuana smokers (234)
(see chapter 5). Olanzapine can reduce psychomimetic effects of
THC in some individuals and its potential benefit is under study
(235). Rimonabant and the anxiolytic buspirone have provided
some efficacy in cannabis addicts on maintenance therapy. Rimon-
abant is a CB1-selective cannabinoid receptor antagonist/inverse
agonist that has been under research for obesity treatment as well
as treatment of nicotine and marijuana addiction. It is not available
in the United States and was pulled from the European market in
October of 2008 due to a high risk to benefit ratio; concerns have
been identified regarding major psychiatric adverse effects (i.e.,
depression and suicide) as well as overall efficacy (167).
OXYTOCIN
Animal research notes that various drugs, including cannabis, can
induce chronic changes in markers of oxytocin function with
resultant social behavior dysfunction. Oxytocin is a neurohy-
pophyseal hormone that has been under research in the regulation
of drug abuse (236). This neuropeptide may serve as a neuro-
modulator on neurotransmission of dopamine in the nucleus
accumbens as well as effects on the hippocampus (236). CNS oxy-
tocin pathways may offer a way of improving mood and social
deficits found in some individuals with drug addiction (237).
Research suggests that use of intranasal oxytocin may be useful in
correcting the negative cannabis (and other illicit drug) effect on
social behavior and perhaps protect the individual from addictive
disorders. (238).
N -ACETYLCYSTEINE
N -acetylcysteine (NAC) has been shown to be useful in manage-
ment of cannabis-dependent adolescents and young adults due
to modulation of glutamate in the nucleus accumbens; it is sug-
gested as an adjuvant treatment (1,200 mg per day) along with
psychological management (239).
OTHERS
Research has failed to validate the use of naltrexone for the treat-
ment of cannabis dependence. Entacapone is a member of the
drug class called nitrocatechols that is used in the management
of Parkinson’s disease. It is an inhibitor of COMT (catechol-O-
methyltransferase) and is under research as a possible drug for
cannabis dependence.
Other drugs under research include lithium, dronabinol,
URB597 [fatty acid amide hydrolase (FAAH) inhibitor], methyl-
lycaconitine, or MLA (nicotinic alpha-7-receptor antagonist), and
endocannabinoid metabolizing enzymes (240).
SUMMARY
Research must provide more specific information on how cannabis
and products derived from cannabis can be useful in medical man-
agement of illness or if the cannabis risks simply outweigh any
potential benefit (241). Does cannabis have advantages over spe-
cific cannabinoids? Can the psychotropic effects of cannabis be
reduced, while utilizing potential medicinal benefits of CB1 recep-
tors activation? Oral cannabis undergoes changes which produce
a narrower therapeutic window and raises questions regarding
whether or not medicinal cannabis products can be given orally
or must be used as a mist or smoke for positive and optimal ben-
efit. It is difficult to find an oral dose that benefits most without
induced unacceptable or unwanted adverse effects in many unwary
consumers (241).
Generalized consumption of the unprocessed C. sativa plant
can lead to considerable public health risks including increased
schizophrenia, psychosis, dependence, and other risks as noted in
this review (242). A medical role for specific cannabinoid com-
pounds remains under active medical research (243, 244). What
is well-known is that there are many potential medical and psy-
chiatric adverse effects to smoking cannabis and its synthetic
derivatives. Links between use of alcohol, cannabis, and other
illicit drugs continues to be unveiled by research (245). Research is
identifying new techniques of cannabis identification to assist the
police and other authorities in forensic investigation (246). Finally,
treatment of an individual with cannabis dependence is very dif-
ficult and requires more research in the twenty-first century (247,
248). Indeed, C. sativa, a controversial plant known for thousands
of years, remains disputatious and contentious in the twenty-first
century (249).
REFERENCES
1. Tashkin DP. Smoked mari-
juana as a cause of lung injury.
Monaldi Arch Chest Dis (2005)
63(2):93–100.
2. Anthony JC. Steppingstone and
gateway ideals: a discussion of
origins, research challenges, and
promising lines of research for
the future. Drug Alcohol Depend
(2012). doi:10.1016/j.drugalcdep.
2012.04.006
3. Fischer B, Jones W, Shuper P,
Rehm J. 12-Month follow-up of
an exploratory “brief interven-
tion” for high-frequency cannabis
use among Canadian university
students. Subst Abuse Treat Prev
Policy (2012) 7(1):15. doi:10.1186/
1747-597X-7-15
4. Shoyama Y, Tamada T, Kurihara
K, Takeuchi A, Taura F, Arai
S, et al. Structure and function
of δ1-tetrahydrocannabinolic acid
(THCA) synthase, the enzyme
controlling the psychoactivity of
Cannabis sativa. J Mol Biol
(2012). doi:10.1016/j.jmb.2012.06.
030
5. Greydanus DE, Reed WJ. Sub-
stance use and abuse in ado-
lescents. In: Greydanus DE,
Patel DR, Pratt HD, Calles JL
Jr, editors. Behavioral Pediatrics.
New York: Nova Science (2009).
p. 426–8.
6. Goullé JP, Saussereau E, Lacroix
C. Delta-9-tetrahydrocannabinol
pharmacokinetics. Ann Pharm Fr
(2008) 66(4):232–44. doi:10.1016/
j.pharma.2008.07.006
7. Tsumura Y, Aoki R, Tokieda Y,
Akutsu M, Kawase Y, Kataoka T,
et al. A survey of the potency
of Japanese illicit cannabis in
fiscal year 2010. Forensic Sci
Int (2012). doi:10.1016/j.forsciint.
2012.04.005
8. Greydanus DE, Patel DR. Sub-
stance abuse in the adolescent. In:
Greydanus DE, Patel DR, Pratt
HD editors. Essential Adolescent
Medicine. New York: McGraw-Hill
(2006). p. 704–5.
9. Clark PA, Capuzzi K, Fick
C. Medical marijuana: med-
ical necessity versus political
agenda. Med Sci Monit (2011)
17(12):RA249–61. doi:10.12659/
MSM.882116
10. Steppan M, Kraus L, Piontek D,
Siciliano V. Are cannabis preva-
lence estimates comparable across
countries and regions? A cross-
cultural validation using search
engine query data. Int J Drug Pol-
icy (2012). doi:10.1016/j.drugpo.
2012.05.002
www.frontiersin.org October 2013 | Volume 1 | Article 42 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greydanus et al. Marijuana: current concepts
11. Thomas KV, Bijlsma L, Cas-
tiglioni S, Covaci A, Emke E,
Grabic R, et al. Comparing
illicit drug use in 19 European
cities through sewage analysis. Sci
Total Environ (2012). doi:10.1016/
j.scitotenv.2012.06.069
12. Kolliakou A, Fusar-Poli P, Atakan
Z. Cannabis abuse and vulnera-
bility to psychosis: targeting pre-
ventive services. Curr Pharm Des
(2012) 18(4):542–9. doi:10.2174/
138161212799316208
13. Teesson M, Slade T, Swift W, Mills
K, Memedovic S, Mewton L, et al.
Prevalence, correlates and comor-
bidity of DSM-IV cannabis use
and cannabis use disorders in Aus-
tralia. Aust NZ J Psychiatry (2012).
doi:10.1177/0004867412460591
14. Greydanus DE, Feucht CL, Hawver
EK. Substance abuse disorders. In:
Greydanus DE, Patel DR, Omar
HA, Feucht C, Merrick J edi-
tors. Adolescent Medicine: Phar-
macotherapeutics in General, Men-
tal, and Sexual Health. Berlin: De
Gruyter (2012). p. 157–99.
15. Greydanus DE, Patel DR. Sub-
stance abuse in adolescents: a
complex conundrum for the clin-
ician. Pediatr Clin North Am
(2003) 59(5):1179–223. doi:10.
1016/S0031-3955(03)00079-8
16. Greydanus DE, Patel DR. Sub-
stance abuse in adolescents:
current concepts. Dis Mon (2005)
51(7):392–431. doi:10.1016/j.
disamonth.2005.10.002
17. Fischer B, Dawe M, McGuire F,
Shuper PA, Capler R, Bilsker D,
et al. Feasibility and impact of
brief interventions for frequent
cannabis users in Canada. J Subst
Abuse Treat (2012). doi:10.1016/j.
jsat.2012.03.006
18. Hibell B, Guttormsson U,
Ahlström S, Balakireva O, Bjar-
nason T, Kokkevi A, et al. ESPAD
(The European School Survey
Project on Alcohol and Other
Drugs) report 2007. Substance Use
Among Students in 35 European
Countries. Stockholm: Swedish
Council Information Alcohol
Other Drugs (2009).
19. Eaton DK, Kann L, Kinchen S,
Shanklin S, Flint KH, Hawkins
J, et al. Youth Risk Behavior
Surveillance (YRBS) US 2009.
MMWR Surveill Summ (2010)
59(SS-5):1–142.
20. Ivanov I, Pearson A, Kaplan K,
Newcorn J. Attention deficit hyper-
activity disorder and comorbid
substance abuse. In: Greydanus
DE, Calles JL Jr, Patel DR, Nazeer A,
Merrick J editors. Clinical Aspects
of Psychopharmacology in Child-
hood and Adolescence. New York:
Nova Science (2011). p. 33–49.
21. Bonn-Miller MO, Harris AH,
Trafton JA. Prevalence of cannabis
use disorders diagnoses among
veterans in 2002, 2008, and 2009.
Psychol Serv (2012). doi:10.1037/
a0027622
22. Mehrpour O, Karrari P, Afshari
R. Recreational use and overdose
of ingested processed cannabis
(Majoon Birjandi) in the eastern
Iran. Hum Exp Toxicol (2012). doi:
10.1177/0960327112446814
23. Lipperman-Kreda S, Lee JP. Boost
your high: cigarette smoking to
enhance alcohol and drug effects
among Southeast Asian Ameri-
can youth. J Drug Issues (2011)
41(4):509–22.
24. Greydanus DE, Feucht C, Patel DR.
Substance abuse disorders in ado-
lescents: pharmacologic manage-
ment. In: Greydanus DE, Calles JL
Jr, Patel DR, Nazeer A, Merrick
J editors. Clinical aspects of psy-
chopharmacology in childhood and
adolescence. New York: Nova Sci-
ence (2011). 178 p.
25. Agrawal A, Budney AJ, Lynskey
MT. The co-occurring use and
misuse of cannabis and tobacco:
a review. Addiction (2012). doi:10.
1111/j1360-0443.2012.03837.x
26. Simmons MS, Tashkin DP. The
relationship of tobacco and mari-
juana smoking characteristics. Life
Sci (1995) 56(23-24):2185–91. doi:
10.1016/0024-3205(95)00206-L
27. American Psychiatric Association.
Diagnostic and Statistical Manual
of Mental Disorders, DSM-IV-TR.
4th ed. Washington, DC: American
Psychiatric Association (2000).
28. Olthuis JV, Darredeau C, Bar-
rett SP. Substance use initia-
tion: the role of simultaneous
polysubstance use. Drug Alcohol
Rev (2012). doi:10.1111/j.1465-
362.2012.00470x
29. Barrett SP, Darredeau C, Pihl RO.
Patterns of simultaneous polysub-
stance use in drug using univer-
sity students. Hum Psychopharma-
col (2006) 21(4):255–63. doi:10.
1002/hup.766
30. Sartor CE, Agrawal A, Lynskey MT,
Duncan AE, Grant JD, Nelson EC,
et al. Cannabis or alcohol first? Dif-
ferences by ethnicity and in risk
for rapid progression to cannabis-
related problems in women. Psy-
chol Med (2013) 43(4):813–23.
doi:10.1017/S0033291712001493
31. Bowes L, Chollet A, Fombonne
E, Galéra C, Melchior M. Life-
time SEP and tobacco and
cannabis use. Eur J Public Health
(2013) 23(2):322–7. 10.1093/eur-
pub/cks06522645240
32. Pesce A, West C, Rosenthal M,
West R, Crews B, Mikel C, et al.
Marijuana correlates with use of
other illicit drugs in a pain patient
population. Pain Physician (2010)
13(3):283–7.
33. O’Brien MS, Comment LA, Liang
KY, Anthony JC. Does cannabis
onset trigger cocaine onset? A case
crossover approach. Int J Methods
Psychiatr Res (2012) 21(1):66–75.
doi:10.1002/mpr.359
34. Malinowska B, Baranowska-
Kuczko M, Schlicker E. Triphasic
blood pressure responses to
cannabinoids: do we understand
the mechanism? Br J Pharmacol
(2012) 165(7):2073–88. doi:10.
1111/j.1476-5381.2011.01747.x
35. Fusar-Poli P, Crippa JA, Bhat-
tacharyva S, Borgwardt SJ,
Allen P, Martin-Santos R, et al.
Distinct effects of {delta}9-
tetrahydrocannabinol and
cannabidiol on neural activa-
tion during emotional processing.
Arch Gen Psychiatry (2009)
66(1):95–105. doi:10.1001/
archgenpsychiatry.2008.519
36. Borgwardt SJ, Allen P, Bhat-
tacharyya S, Fusar-Poli P, Cirppa
JA, Seal ML, et al. Neural basis
of Delta-9-tetrahydrocannabinol
and cannabidiol: effects during
response inhibition. Biol Psychia-
try (2008) 64(11):966–73. doi:10.
1016/j.biopsych.2008.05.011
37. Bergamaschi MM, Queiroz RH,
Zuardi AW, Crippa JA. Safety
and side effects of cannabidiol: a
Cannabis sativa constituent. Curr
Drug Saf (2011) 6(4):237–49. doi:
10.2174/157488611798280924
38. Solinas M, Yasar S, Goldberg SR.
Endocannabinoid system involve-
ment in brain reward processes
related to drug abuse. Pharmacol
Res (2007) 56(5):393–405. doi:10.
1016/j.phrs.2007.09.005
39. Grotenhermen F. Cannabinoids.
Curr Drug Targets CNSNeurol Dis-
ord (2005) 4(5):507–30. doi:10.
2174/156800705774322111
40. Mechoulam R, Parker LA. The
endocannabinoid system and the
brain. Annu Rev Psychol (2012)
64:21–47. doi:10.1146/annurev-
psych-113011-143739
41. Zanettini C, Panlilio LV, Alicki M,
Goldberg SR, Haller J, Yasar S.
Effects of endocannabinoid sys-
tem modulation on cognitive and
emotional behavior. Front Behav
Neurosci (2011) 5:57. doi:10.3389/
fnbeh.2011.00057
42. Marco EM, Garcia-Gutiérrez MS,
Bermúdez-Silva FJ, Moreira FA,
Guimarães F, Manzanares J, et al.
Endocannabinoid system and psy-
chiatry: in search of a neurobio-
logical basis for detrimental and
potential therapeutic effects. Front
Behav Neurosci (2011) 55:63. doi:
10.3389/fnbeh.2011.00063
43. Fattore L, Spano MS, Deiana S,
Melis V, Cossu G, Fadda P, et
al. An endocannabinoid mecha-
nism in relapse to drug seeking:
a review of animal studies and
clinical perspectives. Brain Res Rev
(2007) 53(1):1–16. doi:10.1016/j.
brainresrev.2006.05.003
44. Trezza V, Cuomo VO, Van-
derschuren LJ. Cannabis and
the developing brain: insights
from behavior. Eur J Pharma-
col (2008) 585(2-3):441–52.
doi:10.1016/j.ejphar.2008.01.058
45. Iversen L. Cannabis and the brain.
Brain (2003) 26(Pt 6):1252–70.
doi:10.1093/brain/awg143
46. Marriott KS, Huffman JW. Recent
advances in the development of
selective ligands for the cannabi-
noid CB (2) receptor. Curr Top
Med Chem (2008) 8(3):187–204.
doi:10.2174/156802608783498014
47. Guindon J, Hohmann AG. The
endocannabinoid system and
cancer: therapeutic implica-
tion. Br J Pharmacol (2011)
163(7):1447–63. doi:10.1111/j.
1476-5381.2011.01327.x
48. Caballero A, Tseng KY. Associa-
tion of cannabis use during ado-
lescence, prefrontal CB1 receptor
signaling, and schizophrenia. Front
Pharmacol (2012) 3:101. doi:10.
3389/fphar.2012.00101
49. Hall W. The adverse health effects
of cannabis use: what are they,
and what are their implications
for policy? Int J Drug Policy
(2009) 20(6):458–66. doi:10.1016/
j.drugpo.2009.02.013
50. Hazelkamp A, Fischedick JT.
Cannabis-from cultivar to
chemovar. Drug Test Anal (2012).
doi:10.1002/dta.407
51. Cannabis-based medicines – GW
pharmaceuticals: high CBD, high
THC, medicinal cannabis – GW
pharmaceuticals, THC:CBD.
Drugs R D (2003) 4(5):306–9.
52. Naftali T, Lev LB, Yablecovitch D,
Half E, Konikoff FM. Treatment of
Crohn’s disease with cannabis: an
observational study. Isr Med Assoc
J (2011) 13(8):455–8.
53. Collen M. Prescribing cannabis for
harm reduction. Harm Reduct J
(2012) 9(1):1. doi:10.1186/1477-
7517-9-1
Frontiers in Public Health | Child Health and Human Development October 2013 | Volume 1 | Article 42 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greydanus et al. Marijuana: current concepts
54. Fernandez-Ruiz J. Cannabinoid
drugs for neurological diseases:
what is behind? Rev Neurol (2012)
54(10):613–28.
55. Kraft B. Is there any clinically
relevant cannabinoid-induced
analgesia? Pharmacology (2012)
89(5-6):237–46. doi:10.1159/
000337376
56. Sidney S. Cardiovascular con-
sequences of marijuana use. J
Clin Pharmacol (2002) 42(11
Suppl):64S–70S.
57. Zajicek JP, Hobart JC, Slade A,
Barnes D, Mattison PG, MUSEC
Research Group. Multiple scle-
rosis and extract of cannabis:
results of the MUSEC trial.
J Neurol Neurosurg Psychiatry
(2012) 83(11):1125–32 doi:10.
1136/jnnp-2012-302468
58. Hofmann ME, Frazier CJ. Mar-
ijuana, endocannabinoids, and
epilepsy: potential and chal-
lenges for improved therapeu-
tic intervention. Exp Neurol
(2011) 233:112–25. doi:10.1016/j.
expneurol.2011.11.047
59. Calvaruso G, Pellerito O, Notaro
A, Giuliano M. Cannabinoid-
associated cell death mechanisms
in tumor models (Review). Int
J Oncol (2012). doi:10.3892/ijo.
2012.1476
60. Corey-Bloom J, Wolfson T, Gamst
A, Jin S, Marcotte TD, Bentley H,
et al. Smoked cannabis for spastic-
ity in multiple sclerosis: a random-
ized, placebo-controlled study.
CMAJ (2012) 184(10):1143–50.
doi:10.1503/cmaj.110837
61. Wade D. Evaluation of the
safety and tolerability pro-
file of Sativex: is it reassur-
ing enough? Expert Rev Neu-
rother (2012) 12(4 Suppl):9–14.
doi:10.1586/ern.12.12
62. Jones NA, Glyn SE, Akiyama
S, Hill TD, Hill AJ, Weston
SE, et al. Cannabidiol exerts
anti-convulsant effects in
animal models of tempo-
ral lobe and partial seizures.
Seizure (2012) 21(5):344–52.
doi:10.1016/j.seizure.2012.03.001
63. Caffarel MM, Andradas C, Pérez-
Gómez E, Guzmán M, Sánchez
C. Cannabinoids: a new hope
for breast cancer therapy? Can-
cer Treat Rev (2012). doi:10.1016/
j.ctrv.2012.06.005
64. Styrczewska M, Kulma A,
Ratajczak K, Amarowicz R,
Szope J. Cannabinoid-like
anti-inflammatory compounds
from flax fiber. Cell Mol Biol
Lett (2012) 17(3):479–99.
doi:10.2478/s11658-012-0023-6
65. Esposito G, Filippis DD, Cirillo C,
Luvone T, Capoccia E, Scuderi C,
et al. Cannabidiol in inflammatory
bowel diseases: an overview. Phy-
tother Res (2012). doi:10.1002/ptr.
4781
66. De Vries K, Green AJ. Therapeutic
use of cannabis.Nurs Times (2012)
108(9):12–5.
67. Klumpers LE, Beumer TL, van
Hasselt JG, Lipplaa A, Karger
LB, Kleinloog HD, et al. Novel
delta-9-tetrahydrocannabinol for-
mulation Namisol has benefi-
cial pharmacokinetics and promis-
ing pharmacodynamics effects.
Br J Clin Pharmacol (2011)
72(12):810–6. doi:10.1111/j.1365-
2125.2012.04164.x
68. Tambaro S, Bortolato M.
Cannabinoid-related agents in the
treatment of anxiety disorders;
current knowledge and future
perspectives. Recent Pat CNS
Drug Discov (2012) 7(1):25–40.
doi:10.2174/157488912798842269
69. Schier AR, Ribeiro NP, Silva AC,
Hallak JE, Crippa JA, Nardi AE,
et al. Cannabidiol, a Cannabis
sativa constituent, as an anxiolytic
drug. Rev Bras Psiquiatr (2012)
34(Suppl 1):104–10. doi:10.1590/
S1516-44462012000500008
70. Passie T, Emrich HM, Karst M,
Brandt SD, Halpern JH. Mitigation
of post-traumatic stress symptoms
by Cannabis resin: a review of the
clinical and neurobiological evi-
dence. Drug Test Anal (2012). doi:
10.1002/dta.1377
71. Stern CA, Gazarini L, Takahashi
RN, Guimarães FS, Bertolglio LJ.
On disruption of fear memory
by reconsolidation blockage: evi-
dence from cannabidiol treatment.
Neuropsychopharmacology (2012).
doi:10.1038/npp.2012.63
72. Kolliakou A, Ismail K, Atakan
Z. Why do psychotic patients
use cannabis? Case series. Curr
Pharm Des (2012). doi:10.2174/
138161212802884807
73. Grant I, Atkinson JH, Gouaux
B, Wilsey B. Medical marijuana:
clearing away the smoke. Open
Neurol J (2012) 6:18–25. doi:10.
2174/1874205X01206010018
74. Fattore L, Fratta W. Beyond THC:
the new generation of cannabi-
noid designer drugs. Front Behav
Neurosci (2011) 5:60. doi:10.3389/
fnbeh.2011.00060
75. Berkovitz R, Arieli M, Marom
E. Synthetic cannabinoids – the
new “legal high” drugs. Harefuah
(2011) 150(12):884–7.
76. Hilderbrand RL. High-
performance sport, marijuana,
and cannabimimetics. J Anal
Toxicol (2011) 35(9):624–37.
doi:10.1093/anatox/35.9.624
77. Castellanos D, Thornton G. Syn-
thetic cannabinoid use: recogni-
tion and management. J Psychiatr
Pract (2012) 18(2):86–93. doi:10.
1097/01.pra.0000413274.09305.9c
78. Seely KA, Lapoint J, Moran JH, Fat-
tore L. Spice drugs are more than
harmless herbal blends: a review of
the pharmacology and toxicology
of synthetic cannabinoids. Prog
Neuropsychopharmacol Biol Psychi-
atry (2012). doi:10.1016/j.pnpbp.
2012.04.017
79. Bebarta VS, Ramirez S, Varney SM.
Spice: a new “legal” herbal mix-
ture abused by young active duty
military personnel. Subst Abus
(2012) 33(2):191–4. doi:10.1080/
08897077.2011.637610
80. Karila Petit A, Cottencin O, Coscas
S, Reynaud M. Synthetic drugs: the
new low-cost landscape of drugs.
Rev Prat (2012) 62(5):664–6.
81. Rosenbaum CD, Carreiro SP,
Babu KM. Here today, gone
tomorrow….back again? A
review of herbal marijuana
alternatives (K2, Spice), syn-
thetic cathinones (bath salts),
Kratom, Salvia divinorum,
methoxetamine, and piper-
azines. J Med Toxicol (2012).
doi:10.1007/s13181-011-0202-2
82. Funada M. Pharmacological prop-
erties and dependence liabilities
of synthetic cannabinoids. Nihon
Arukoru Yakubutsu Igakkai Zasshi
(2010) 45(3):167–74.
83. Johnson LA, Johnson RL, Alfonzo
C. Spice: a legal marijuana
equivalent. Mil Med (2011)
176(6):718–20.
84. Schneir AB, Cullen J, Ly BT.
“Spice” girls: synthetic cannabi-
noid intoxication. J Emerg Med
(2011) 40(3):296–9. doi:10.1016/j.
jemermed.2010.10.014
85. Ginsburg BC, McMahon LR,
Sanchez JJ, Javors MA. Purity of
synthetic cannabinoids sold online
for recreational use. J Anal Toxicol
(2012) 36(1):66–8. doi:10.1093/
jat/bkr018
86. De Backer B, Maebe Verstraete
AG, Charlier C. Evolution of
the content of THC and other
major cannabinoids in drug-type
cannabis cuttings and seedlings
during growth of plants. J Foren-
sic Sci (2012). doi:10.1111/j.1556-
4029.2012.02068
87. Köhnemann S, Nedele J, Schwotzer
D, Morzfeld J, Pfeiffer H. The vali-
dation of a 15 STR multiplex PCR
for Cannabis species. Int J Legal
Med (2012). doi:10.1007/s00414-
012-0706-6
88. Mura P, Saussereau E, Brunet
B, Goulié JP. Workplace test-
ing of drugs of abuse and psy-
chotropic drugs. Ann Pharm Fr
(2012) 70(3):120–32. doi:10.1016/
j.pharma.2012.03.002
89. Salomone A, Gerace E, E’Urso F,
Di Corcia D, Vincenti M. Simul-
taneous analysis of several syn-
thetic cannabinoids, THC, CBD,
and CBN, in hair by ultra-high
performance liquid chromatogra-
phy tandem mass spectrometry.
Method validation and application
to real samples. J Mass Spectrom
(2012) 47(5):604–12. doi:10.1002/
jms.2988
90. Adverse effects of cannabis. Pre-
scrire Int (2011) 20(112):18–23.
91. Kalant H. Adverse effects of
cannabis on health: an update of
the literature since 1996. Prog Neu-
ropsychopharmacol Biol Psychiatry
(2004) 28(5):849–63. doi:10.1016/
j.pnpbp.2004.05.027
92. Monshouwer K, Van Dorsselaer
S, Verdurmen J, Bogt TT, De
Graaf R, Vollegergh W. Cannabis
use and mental health in sec-
ondary children. Findings from
a Dutch survey. Br J Psychiatry
(2006) 188:148–53. doi:10.1192/
bjp.188.2.148
93. Lee MH, Hancox RJ. Effects
of smoking cannabis on lung
function. Expert Rev Respir Med
(2011) 5(4):537–46. doi:10.1586/
ers.11.40
94. Howden ML, Naughton MT.
Pulmonary effects of marijuana
inhalation. Expert Rev Respir Med
(2011) 5(1):87–92. doi:10.1586/
ers.10.87
95. Zarfin Y, Yefet E, Abozaid S,
Nasser WM, Finkelstein Y. Infant
with altered consciousness after
cannabis passive inhalation. Child
Abuse Negl (2012) 36(2):81–3. doi:
10.1016/j.chiabu.2011.09.011
96. Molly C, Mory O, Basset T, Patural
H. Acute cannabis poisoning in a
10-month-old infant. Arch Pediatr
(2012). doi:10.1016/j.arcped.2012.
04.018
97. Mallaret M, Dal’Bo-Rohrer D,
Demattéis M. Adverse effects
of marijuana. Rev Prat (2005)
55(1):41–9.
98. Davis GP, Gunderson EW. Evalua-
tion of chronic cough should con-
sider cannabis use. Am Fam Physi-
cian (2012) 85(7):680–2.
99. Benich JJ 3rd, Carek PJ. Evalua-
tion of the patient with chronic
cough. Am Fam Physician (2011)
84(8):887–92.
www.frontiersin.org October 2013 | Volume 1 | Article 42 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greydanus et al. Marijuana: current concepts
100. Bonnet U. Chronic cannabis abuse,
delta-9-tetrahydrocannabinol and
thyroid function and thyroid func-
tion. Pharmacopsychiatry (2012).
doi:10.1055/s-0032-1316342
101. Fatma H, Mouna B, Leila M, Rad-
houane D, Taoufik N. Cannabis: a
rare case of acute pancreatitis. Clin
Res Hepatol Gastroenterol (2012).
doi:10.1016/j.clinre.2012.05.004
102. Spadari M, Canioni D, Gregoire E,
Drouet G, Bourdon JA, Arditti J,
et al. Cannabis body packing: two
case reports. Clin Toxicol (Phila)
(2011) 49(9):862–4. doi:10.3109/
15563650.2011.623679
103. Simonetto DA, Oxentenko AS,
Herman ML, Szostek JH. Cannabi-
noid hyperemesis: a case series
of 98 patients. Mayo Clin Proc
(2012) 87(2):114–9. doi:10.1016/j.
mayocp.2011.10.005
104. Fleig S, Brunkhorst R. Hypereme-
sis and a high water bill. Z Gas-
troenterol (2011) 49(11):1479–81.
doi:10.1055/s-0029-1246107
105. Galli JA, Sawaya RA, Frieden-
berg FK. Cannabinoid hypereme-
sis syndrome. Curr Drug Abuse Rev
(2011) 4(4):241–9. doi:10.2174/
1874473711104040241
106. Wallace EA, Andrews SE, Gar-
many CL, Jelley MJ. Cannabinoid
hyperemesis syndrome: literature
review and proposed diagnosis and
treatment algorithm. South Med
J (2011) 104(9):659–64. doi:10.
1097/SMJ.0b013e3182297d57
107. Nicolson SE, Denysenko L, Mul-
care JL, Vito JP, Chabon B.
Cannabinoid hyperemesis syn-
drome: a case series and review of
previous reports. Psychosomatics
(2012) 53(3):212–9. doi:10.1016/j.
psym.2012.01.003
108. Luther V, Yap L. A hot bath to calm
what ails you: the Cannabis Hyper-
emesis Syndrome. Acute Med
(2012) 11(1):23–4.
109. Wild K, Wilson H. Cannabi-
noid hyperemesis. Emerg Med J
(2012) 29(1):67–9. doi:10.1136/
emj.01.2010.2605rep
110. Cho CM, Hirsch R, Johnstone S.
General and oral health implica-
tions of cannabis use. Aust Dent
J (2005) 50(2):70–4. doi:10.1111/
j.1834-7819.2005.tb00343.x
111. Maloney WJ. Significance of
cannabis use to dental prac-
tice. J Mich Dent Assoc (2011)
93(11):44–8.
112. Maloney WJ. Significance of
cannabis use to dental practice.
Todays FDA (2012) 24(1):43–5.
113. Lopes CF, de Angelis BB, Pru-
dente HM, de Souza BV, Car-
doso SV, de Azambuja Ribeiro
RI. Concomitant consumption of
marijuana, alcohol, and tobacco
in oral squamous cell carci-
noma development and progres-
sion: recent advances and chal-
lenges. Arch Oral Biol (2012). doi:
10.1016/j.archoralbio.2012.05.006
114. Pletcher MJ, Vittinghoff E, Kalhan
R, Richman J, Safford M, Sid-
ney S, et al. Association between
marijuana exposure and pul-
monary function over 20 years.
JAMA (2012) 307(2):173–81. doi:
10.1001/jama.2011.1961
115. Ribeiro A, Ferraz-de-Paula
V, Pinheiro ML, Vitoretti LB,
Mariano-Souza DP, Quinteiro-
Filho WM, et al. Cannabidiol, a
non-psychotropic plant-derived
cannabinoid, decreases inflam-
mation in a murine model of
acute lung injury: role for the
adenosine A (2A) receptor. Eur J
Pharmacol (2012) 678(1-3):78–85.
doi:10.1016/j.ejphar.2011.12.043
116. Tashkin DP. Airway effects of mar-
ijuana, cocaine, and other inhaled
illicit agents. Curr Opin Pulm Med
(2001) 7(2):43–61. doi:10.1097/
00063198-200103000-00001
117. Pfeifer AK, Lange P. Pulmonary
consequences of marijuana
smoking. Ugeskr Laeger (2006)
168(1):1743–6.
118. Szyper-Kravitz M, Lang R, Manor
Y, Lahav M. Early invasive pul-
monary aspergillosis in a leukemia
patient linked to Aspergillus conta-
minated marijuana smoking. Leuk
Lymphoma (2001) 42(6):1433–7.
doi:10.3109/10428190109097776
119. Aldington S, Williams S, Nowitz
M, Weatherall M, Pritchard A,
McNaughton A, et al. Effects of
cannabis on pulmonary structure,
function, and symptoms. Tho-
rax (2007) 62(12):1058–63. doi:10.
1136/thx.2006.077081
120. Wu TC, Tashkin DP, Djahed
B, Rose JE. Pulmonary hazards
of smoking marijuana as com-
pared with tobacco. N Engl J
Med (1988) 318(6):347–51. doi:10.
1056/NEJM198802113180603
121. Reid PT, Macleod J, Robertson JR.
Cannabis and the lung. Cannabis
and the lung. J R Coll Physicians
Edinb (2010) 40(4):328–33. doi:
10.4997/JRCPE.2010.417
122. Tan WC, Lo C, Jong A, Xing
L, Fizgerald MJ, Vollmer
WM, et al. Marijuana and
chronic obstructive lung dis-
ease: a population-based study.
CMAJ (2009) 180(8):814–20.
doi:10.1503/cmaj.081040
123. Van Hoozen BE, Cross CE. Mar-
ijuana. Respiratory tract effects.
Clin Rev Allergy Immunol (1997)
15(3):243–69.
124. Kothadia JP, Chhabra S, Marcus
A, May M, Saraiya B, Jabbour SK.
Anterior mediastinal mass in a
young marijuana smoker: a rare
case of small-cell lung cancer. Case
Report Med (2012) 2012:754231.
doi:10.1155/2012/754231
125. Quoix E. Novel epidemiology in
lung cancer-nonsmokers, women
and cannabis. Rev Mal Respir
(2007) 24(8 Pt 2):S20–5.
126. Chen AL, Chen TJ, Braver-
man ER, Acuri V, Kemer M,
Varshavskiy M, et al. Hypothe-
sizing that marijuana smokers
are at significantly lower risk
of carcinogenicity relative to
tobacco-non-marijuana smokers:
evidence based on statistical
reevaluation of current lit-
erature. J Psychoactive Drugs
(2008) 40(3):263–72. doi:10.1080/
02791072.2008.10400641
127. Quoix E. What is new in the epi-
demiology of lung cancer: non-
smokers, women, and the role
of cannabis. Rev Prat (2009)
59(7):920–4.
128. Quoix E, Lemarié E. Epidemiolog-
ical novelties in lung cancer. Rev
Mal Respir (2011) 28(8):1048–58.
doi:10.1016/j.rmr.2010.12.015
129. Montecucco F, Di Marzo V. At
the heart of the matter: the endo-
cannabinoid system in cardiovas-
cular function and dysfunction.
Trends Pharmacol Sci (2012). doi:
10.1016/j.tips.2012.03.002
130. Pratap B, Komiyenko A. Toxic
effects of marijuana on the cardio-
vascular system.Cardiovasc Toxicol
(2011) 2(2):143–8. doi:10.1007/
s12012-011-9150-y
131. Romero-Puche AJ, Trigueros-Ruiz
N, Cerdán-Sánchez MC, Pérez-
Lorente F, Roldán D, Vicente-Vera
T. Brugada electrocardiogram pat-
tern induced by cannabis. Rev
Esp Cardiol (2012). doi:10.1016/j.
recesp.2012.01.013
132. Irani F, Kasmani R, Kanjwai
Y. Hyperkalemia and cocaine
induced Brugada-type electro-
cardiogram. Eur J Emerg Med
(2010) 17(2):113–5. doi:10.1097/
MEJ.0b013e32832e46d1
133. Bailly C, Merceron O, Hammoudi
N, Dorent R, Michel PL. Cannabis
induced acute coronary syndrome
in a young female. Int J Cardiol
(2010) 143(1):e4–6. doi:10.1016/j.
ijcard.2008.11.200
134. Cappelli F, Lazzeri C, Gensini
GF, Valente S. Cannabis: a trig-
ger for acute myocardial infarc-
tion? A case report. J Cardiovasc
Med (2008) 9(7):725–8. doi:10.
2459/JCM.0b013e3282f2cd0d
135. Singla S, Sachdeva R, Mehta JL.
Cannabinoids and atherosclerotic
coronary heart disease. Clin Car-
diol (2012). doi:10.1002/clc.21962
136. Yurtdas M, Aydin MK. Acute
myocardial infarction in a young
man; fatal blow of the mari-
juana: a case report. Korean Circ
J (2012) 42(9):641–5. doi:10.4070/
kcj.2012.42.9.641
137. Asbridge M, Hayden JA,
Cartwright JL. Acute cannabis
consumption and motor vehicle
collision risk: systemic review of
observational studies and meta-
analysis. BMJ (2012) 344:e536.
doi:10.1136/bmj.e536
138. Li MC, Brady JE, DiMaggio CJ,
Lusardi AR, Tzong KY, Li G.
Marijuana use and motor vehi-
cle crashes. Epidemiol Rev (2012)
34(1):65–72. doi:10.1093/epirev/
mxr017
139. Drabek M, Andysz A. Effects of
marijuana and amphetamine (and
its derivatives) on driving per-
formance based on the driving
simulator studies. Med Pr (2011)
62(5):551–63.
140. Johnson MB, Kelley-Baker G, Voas
RB, Lacey JH. The prevalence
of cannabis-involved driving in
California. Drug Alcohol Depend
(2012) 123(1-3):105–9. doi:10.
1016/j.drugalcdep.2011.10.023
141. Bosker WM, Kuypers KP, The-
nunissen EL, Surinx A, Blanken-
spoor RJ, Skopp G, et al. Medicinal
∆(9)-tetrahydrocannabinol
(dronabinol) impairs on-the-road
driving performance of occasional
and heavy cannabis users but is
not detected in Standard Field
Sobriety Tests. Addiction(2012)
107(10):1837–44. doi:10.1111/j.
1360-0443.2012.03928.x
142. Barrio G, Jimenez-Mejias E, Pulido
J, Lardelli-Claret P, Bravo MJ, de
la Fuenta L. Association between
cannabis use and non-traffic
injuries. Accid Anal Prev (2012)
47:172–6. doi:10.1016/j.aap.2012.
01.002
143. Campos DR, Yonamine M, de
Morases Moreau RL. Marijuana
as doping in sports. Sports Med
(2003) 33(6):395–9. doi:10.2165/
00007256-200333060-00001
144. Saugy M, Avois L, Saudan C,
Robinson N, Giroud C, Man-
gin P, et al. Cannabis and
sports. Br J Sports Med (2006)
40(Suppl 1):13–5. doi:10.1136/
bjsm.2006.027607
145. Pope HG Jr, Gruber AJ,
Yurgelun-Todd D. The residual
Frontiers in Public Health | Child Health and Human Development October 2013 | Volume 1 | Article 42 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greydanus et al. Marijuana: current concepts
neuropsychological effects of
cannabis: the current status of
research. Drug Alcohol Depend
(1995) 38(1):25–34. doi:10.1016/
0376-8716(95)01145-O
146. Martin-Santos F, Fagundo AB,
Crippa JA, Atakan Z, Bhat-
tacharyya S, Allen P, et al. Neu-
roimaging in cannabis use: a sys-
temic review of the literature. Psy-
cholMed (2010) 40(3):383–98. doi:
10.1017/S0033291709990729
147. Crippa JA, Lacerda AL, Amaro
E, Busatto Filho G, Zuardi AW,
Bressan RA. Brain effects of
cannabis – neuroimaging find-
ings. Rev Bras Psiquiatr (2005)
27(1):70–8.
148. Schreiner AA, Dunn ME. Resid-
ual effects of cannabis use on neu-
rocognitive performance after pro-
longed abstinence: a meta-analysis.
Exp Clin Psychopharmacol (2012).
doi:10.1037/a0029117
149. Montgomery C, Seddon AL,
Fisk JE, Murphy PN, Jansari A.
Cannabis-related deficits in real-
world memory. Hum Psychophar-
macol (2012) 27(2):217–25.
doi:10.1002/hup.1273
150. Marmorstein NR, Iacono WG,
McGue M. Associations between
substance use disorders and major
depression in parents and late
adolescent-emerging adult off-
spring: an adoption study. Addic-
tion (2012). doi:10.1111/j.1360-
0443.2012.03934.x
151. Harvey MA, Sellman JD, Porter
RJ, Frampton CM. The relation-
ship between non-acute adolescent
cannabis use and cognition. Drug
Alcohol Rev (2007) 26(3):309–19.
doi:10.1080/09595230701247772
152. Sundram S. Cannabis and
neurodevelopment: impli-
cations for psychiatric dis-
orders. Hum Psychophar-
macol (2006) 21(4):245–54.
doi:10.1002/hup.762
153. Schneider M. Puberty as a highly
vulnerable developmental period
for the consequences of cannabis
exposure. Addict Biol (2008)
13(2):253–63. doi:10.1111/j.1369-
1600.2008.00110.x
154. Dinieri JA, Hurd YL. Rat mod-
els of prenatal and adolescent
cannabis exposure. Methods Mol
Biol (2012) 829:231–42. doi:10.
1007/978-1-61779-458-2_14
155. Degenhardt L, Coffey C, Roma-
niuk H, Swift W, Carlin JB, Hall
WD, et al. The persistence of
the association between adoles-
cent cannabis use and common
mental disorders into young
adulthood. Addiction (2012).
doi:10.1111/j.1360-0443.2012.
04015.x
156. Urban NB, Slifstein M, Thomp-
son JL, Xu X, Grigis RR, Raheja
S, et al. Dopamine release in
chronic cannabis uers: a [(11)
C] raclopride positron emission
tomography study. Biol Psychia-
try (2012). doi:10.1016/j.biopsych.
2011.12.018
157. Zalesky A, Solowij N, Yücel M,
Lubman DI,Takagi M,Harding IH,
et al. Effect of long-term cannabis
use on axonal fibre connectivity.
Brain (2012). doi:10.1093/brain/
aws136
158. Leach LS, Butterworth P. The
effect of early onset common
mental disorders on educational
attainment in Australia. Psychiatry
Res (2012). doi:10.1016/j.psychres.
2012.03.040
159. Yücel M, Solowij N, Respondek C,
Whittle S, Fornito A, Pantelis C,
et al. Regional brain abnormalities
associated with long-term heavy
cannabis use. Arch Gen Psychia-
try (2008) 65(6):694–701. doi:10.
1001/archpsyc.65.6.694
160. Abushi H, Akirav I. Short-and
long-term cognitive effects of
chronic cannabinoids administra-
tion in late-adolescence rats. PLoS
ONE (2012) 7(2):e31731. doi:10.
1371/journal.pone.0031731
161. Gordon SM, Tulak F, Tron-
cale J. Prevalence and charac-
teristics of adolescent patients
with co-occurring ADHD and
substance dependence. J Addict
Dis (2004) 23:31–40. doi:10.1300/
J069v23n04_03
162. Dennis M, Godley SH, Diamond
G, Tims FM, Babor T, Donaldson
J, et al. The Cannais Youth Treat-
ment (CYT) Study: main findings
from two randomized trials. J Subst
Abuse Treat (2004) 27(3):197–213.
doi:10.1016/j.jsat.2003.09.005
163. Han S, Yang BZ, Kranzler HR,
Oslin D, Anton R, Farrer LA, et
al. Linkage analysis followed by
association shown NRG1 associ-
ated with cannabis dependence in
African Americans. Biol Psychia-
try (2012). doi:10.1016/j.biopsych.
2012.02.038
164. Hürlimann F, Kupferschmid S,
Simon AE. Cannabis-induced
depersonalization disorder in
adolescence. Cannabis-induced
depersonalization disorder in
adolescents. Neuropsychobi-
ology (2012) 65(3):141–6.
doi:10.1159/000334605
165. Horwood LJ, Fergusson DM, Cof-
fey C, Patton GC, Tait R, Smart
D, et al. Cannabis and depression:
an integrative data analysis of four
Australasian cohorts. Drug Alco-
hol Depend (2012). doi:10.1016/j.
drugalcdep.2012.06.002
166. Van Dam NT, Bedi G, Earley-
wine M. Characteristics of clini-
cally anxious versus non-anxious
regular, heavy marijuana users.
Addict Behav (2012). doi:10.1016/
j.addbeh.2012.05.021
167. Budney AJ. Should cannabis with-
drawal disorder be included in
DSM-5? Psychiatr Times (2011)
28(2):48–50.
168. Budney AJ, Hughes JR, Moore BA,
Vandrey R. Review of the validity
and significance of cannabis with-
drawal syndrome. Am J Psychiatry
(2004) 161:1967–77. doi:10.1176/
appi.ajp.161.11.1967
169. Budney AJ, Hughes JR. The
cannabis withdrawal syndrome.
Curr Opin Psychiatry (2006)
19:233–8. doi:10.1097/01.yco.
0000218592.00689.e5
170. Crowley TJ, MacDonald MJ, Whit-
more EA. Cannabis dependence,
withdrawal, and reinforcing effects
among adolescents with conduct
symptoms and substance use
disorders. Drug Alcohol Depend
(1998) 50:27–37. doi:10.1016/
S0376-8716(98)00003-9
171. Vandrey RG, Budney AJ, Hughes
JR, Liguoria A. A within-subject
comparison of withdrawal
symptoms during abstinence
from cannabis, tobacco, and
both substances. Drug Alcohol
Depend (2008) 92(1-3):48–54.
doi:10.1016/j.drugalcdep.2007.06.
010
172. Arendt M, Rosenberg R, Fjord-
back L, Brandholdt J, Foldager L,
Sher L, et al. Testing the self-
medication hypothesis of depres-
sion and aggression in cannabis-
dependent subjects. Psychol Med
(2007) 37(7):935–45. doi:10.1017/
S0033291706009688
173. Calles JL Jr, Nazeer A. Aggressive
and violent behavior. In: Grey-
danus DE, Calles JL Jr, Patel DR,
Nazeer A, Merrick J editors. Clin-
ical Aspects of Psychopharmacology
in Childhood and Adolescence. New
York: Nova Science Publishers Inc
(2011). 106 p.
174. Schacht JP, Hutchinson KE, Fil-
bey FM. Associations between
cannabinoid-receptor-1 (CNR1)
variation and hippocampus
and amygdale volumes in
heavy cannabis users. Neu-
ropsychopharmacology (2012).
doi:10.1038/npp.2012.92
175. Haney M, Hart CL, Vosburg KD.
Marijuana withdrawal in humans:
effects of oral THC or dival-
proex. Neuropsychopharmacology
(2004) 29:158–70. doi:10.1038/sj.
npp.1300310
176. Milin R, Manion I, Dare G,
Walker S. Prospective assessment
of cannabis withdrawal in adoles-
cents with cannabis dependence: a
pilot study. JAmAcadChildAdolesc
Psychiatry (2008) 47:174–8. doi:
10.1097/chi.0b013e31815cdd73
177. Cornelius JR, Chung T, Mar-
tin C, Wood DS, Clark DB.
Cannabis withdrawal is com-
mon among treatment seeking
adolescents with cannabis depen-
dence and major depression, and
is associated with rapid relapse to
dependence. Addict Behav (2008)
103:787–99. doi:10.1016/j.addbeh.
2008.02.001
178. Gorelick DA, Levin KH, Cop-
ersino ML, Heishman SJ, Liu
F, Boggs DL, et al. Diagnostic
criteria for cannabis withdrawal
syndrome. Drug Alcohol Depend
(2012) 123(1-3):141–7. doi:10.
1016/j.drugalcdep.2011.11.007
179. Gardner EL. Addictive potential
of cannabinoids: the underlying
neurobiology. Chem Phys Lipids
(2005) 121(1-2):267–90. doi:10.
1016/S0009-3084(02)00162-7
180. Cooper ZD, Haney M. Cannabis
reinforcement and dependence:
role of cannabinoid CB1 receptor.
Addict Biol (2008) 13(2):188–95.
doi:10.1111/j.1369-1600.2007.
00095.x
181. Cooper ZD, Haney M. Actions
of delta-9-tetrahydrocannabinol
in cannabis: relation to use,
abuse, dependence. Int Rev Psy-
chiatry (2009) 2192:104–12.
doi:10.1080/09540260902782752
182. Gardner EL. Endocannabinoid sig-
naling system and brain reward:
emphasis on dopamine. Phar-
macol Biochem Behav (2005)
81(2):263–84. doi:10.1016/j.pbb.
2005.01.032
183. Gardner EL. Addiction and brain
reward and antireward path-
ways. Adv Psychosom Med (2011)
30:22–60. doi:10.1159/000324065
184. Bossong MG, van Berckel BN,
Boellaard R, Zuurman L, Schuit
RC, Windhorst AD, et al. Delta
9-tetrahydrocannabinol induces
dopamine release in the human
striatum. Neuropsychopharma-
cology (2009) 34(3):759–66.
doi:10.1038/npp.2008.138
185. Horey JT, Mariani JJ, Cheng WY,
Bisaqa A, Sullivan M, Nunes
E, et al. Comparison of sub-
stance use milestones in cannabis-
and cocaine-dependent patients. J
www.frontiersin.org October 2013 | Volume 1 | Article 42 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greydanus et al. Marijuana: current concepts
Addict Dis (2012) 31(1):60–6. doi:
10.1080/10550887.2011.642753
186. Goldstein RZ, Volkow ND. Dys-
function of the prefrontal cortex in
addiction: neuroimaging findings
and clinical implications. Nat Rev
Neurosci (2011) 12(11):652–69.
doi:10.1038/nrn3119
187. Goldstein RZ, Volkow ND. Drug
addiction and its underlying neu-
robiological basis: neuroimaging
evidence for the involvement of
the frontal cortex. Am J Psychia-
try (2002) 159(10):1642–52. doi:
10.1176/appi.ajp.159.10.1642
188. Feil J, Sheppard D, Fitzgerald PB,
Yücel M, Lubman DI, Bradshaw
JL. Addiction, compulsive drug
seeking, and the role of frontos-
triatal mechanisms in regulating
inhibitory control. Neurosci Biobe-
hav Rev (2010) 35(2):248–75. doi:
10.1016/j.neubiorev.2010.03.001
189. Rotter A, Bayerlein K, Hansbauer
M, Weiland J, Sperling W, Korn-
huber J, et al. Orexin A expres-
sion and promoter methylation
in patients with cannabis depen-
dence in comparison to nicotine-
dependent cigarette smokers and
nonsmokers. Neuropsychobiology
(2012) 66(2):126–33. doi:10.1159/
000339457
190. Schafer G, Feilding A, Morgan
CG, Agathangelou M, Freeman TP,
Valerie Curran H. Investigating the
interaction between schizotypy,
divergent thinking, and cannabis
use.ConsciousCogn (2002). doi:10.
1016/j.concog.2011.11.009
191. Galvez-Buccollini JA, Proal
AC, Tomaselli V, Trachtenberg
M, Coconcea C, Chun J, et
al. Association between age at
onset of psychosis and age at
onset of cannabis use in non-
affective psychosis. Schizophr
Res (2012) 139(1-3):157–60.
doi:10.1016/j.schres.2012.06.007
192. Giovanni M, Giuseppe DI, Gianna
S, Domenico DB, Luisa DR, Mas-
simo DG. Cannabis use and psy-
chosis: theme introduction. Curr
Pharm Des (2012) 18(32):4991–8.
doi:10.2174/138161212802884627
193. Leweke FM, Koethe D. Cannabis
and psychiatric disorders: it is not
only addiction. Addict Biol (2008)
13(2):264–75. doi:10.1111/j.1369-
1600.2008.00106.x
194. Nazeer A, Calles JL Jr. Schizophre-
nia in children and adolescents.
In: Greydanus DE, Calles JL Jr,
Patel DR, Nazeer A, Merrick J edi-
tors.Clinical Aspects of Psychophar-
macology in Childhood and Ado-
lescence. New York: Nova Science
(2011). 152 p.
195. Van Dijk D, Koeter MW, Hijman R,
Kahn RS, van den Bring W. Effect
of cannabis use on the course of
schizophrenia in male patients: a
prospective cohort study. Scizophr
Res (2012). doi:10.1016/j.schres.
2012.01.016
196. Bossong MG, Niesink RJ. Ado-
lescent brain maturation, the
endogenous cannabinoid system,
and the neurobiology of cannabis-
induced schizophrenia. Prog
Neurobiol (2010) 92(3):370–85.
doi:10.1016/j.pneurobio.2010.06.
010
197. Rapp C, Bugra H, Riecher-Rössler
A, Borgwardt S. Effects of cannabis
use on human brain structure
in psychosis: a systematic review
combining in vivo structural neu-
roimaging and post-mortem stud-
ies.Curr PharmDes (2012). doi:10.
2174/138161212802884861
198. Khan MK, Usmani MA, Hanif
SA. A case of self amputation
of penis by cannabis induced
psychosis. J Forensic Leg Med
(2012) 19(6):355–7. doi:10.1016/j.
jflm.2012.02.023
199. Barrowclough C, Emsley R, Eisner
E, Beardmore R, Wykes T. Does
change in cannabis use in estab-
lished psychosis affect clinical out-
come? Schizophr Bull (2011). doi:
10.1093/schbul/sbr152
200. Leweke FM. Anandamide dysfunc-
tion in prodromal and estab-
lished psychosis. Curr Pharm Des
(2012) 18(32):5188–93. doi:10.
2174/138161212802884843
201. Decoster J, van Os J, Myin-
Germeys I, De Hert M, van
Winkel R. Genetic variation under-
lying psychosis-inducing effects of
cannabis: critical review and future
directions.CurrPharmDes (2012).
doi:10.2174/138161212802884591
202. Serafini G, Pompili M, Innamorati
M, Rihmer Z, Sher L, Girardi P.
Can cannabis increase the suicide
risk in psychosis? A critical review.
Curr Pharm Des (2012). doi:10.
2174/138161212802884663
203. Hermann D, Schneider M. Poten-
tial protective effects of cannabid-
iol on neuroanatomical alter-
ations in cannabis users and psy-
chosis: a critical review. Curr
Pharm Des (2012). doi:10.2174/
138161212802884825
204. Lev-Ran S, Aviram A, Braw Y,
Nitzan U, Ratzoni G, Fennig S.
Clinical correlates of cannabis
use among adolescent psychiatric
inpatients. Eur Psychiatry (2012).
doi:10.1016/j.eurpsy.2011.11.002
205. Auther AM, McLaughlin D, Car-
rión RE, Naqachandran P, Correll
CU, Cornblatt BA. Prospective
study of cannabis use in adoles-
cents at clinical high risk for psy-
chosis: impact of conversion to
psychosis and functional outcome.
Psychol Med (2012) 30:1–13. doi:
10.1017/S0033291712000803
206. Zuardi AW, Crippa JA, Hallak
JE, Bhattacharyya S, Atakan Z,
Martin-Santos R, et al. A critical
review of the antipsychotic effects
of Cannabidiol: 30 years of trans-
lational investigation. Curr Pharm
Des (2012) 18(32):5131–40. doi:
10.2174/138161212802884681
207. Bhattacharyya S, Crippa JA,
Allen P, Martin-Santos R, Borg-
wardt S, Fusar-Poli P, et al.
Induction of psychosis byδ9-
tetrahydrocannabinol reflects
modulation of prefrontal and stri-
atal function during attentional
salience processing. Arch Gen
Psychiatry (2012) 69(1):27–36.
doi:10.1001/archgenpsychiatry.
2011.161
208. Blum K, Gardner E, Oscar-
Berman M, Gold M. “Liking” and
“Wanting” linked to reward defi-
ciency syndrome (RDS): hypoth-
esizing differential responsivity
in brain reward circuitry. Curr
Pharm Des (2012). doi:10.2174/
138161212798919110
209. Bailén AJR, Quesada PS, Val-
ladares MA. Decision making in
cannabis users. Adicciones (2012)
24(2):161–72.
210. Van Ours JC, Williams J. The
effects of cannabis use on physical
and mental health. J Health Econ
(2012) 31(4):564–77. doi:10.1016/
j.jhealeco.2012.04.003
211. Schifano F, Martinotti G, Cun-
niff A, Reissner V, Scherbaum
N, Ghodse H. Impact of an
18-month, NHS-based, treatment
exposure for heroin dependence:
results from the London Area Treat
2000 Study. Am J Addict (2012)
21(3):268–73. doi:10.1111/j.1521-
0391.2012.00226.x
212. Porath-Waller AJ, Beasley E, Beir-
ness DJ. A meta-analytic review
of school-based prevention for
cannabis use. Health Educ Behav
(2010) 37(5):709–23. doi:10.1177/
1090198110361315
213. Teesson M, Newton NC, Bar-
rett EL. Australian school-based
prevention programs for alcohol
and other drugs: a systemic
review. Drug Alcohol Rev (2012).
doi:10.1111/j.1465-3362.2012.
00420.x
214. De Looze M, Harakeh Z, van Dors-
selaer SA, Raaijmakers QA, Volle-
bergh WH, Bogt TF. Explaining
educational differences in adoles-
cent substance use and early sex-
ual debut: the role of parents and
peers. J Adolesc (2012). doi:10.
1016/j.adolescence.2012.02.009
215. Yap MB, Reavley NJ, Jorm AF.
Young people’s beliefs about the
harmfulness of alcohol, cannabis,
and tobacco for mental disor-
ders: findings from two Australian
national youth surveys. Addic-
tion (2012) 107(4):838–47. doi:10.
1111/j.1360-0443.2011.03732.x
216. Gillespie NA, Lubke GH, Gard-
ner CO, Neale MC, Keanler
KS. Two-part random effects
growth modeling to identify
risks associated with alcohol
and cannabis initiation, initial
average use, and changes in drug
consumption in s sample of adult,
male twins. Drug Alcohol Depend
(2011). doi:10.1016/j.drugalcdep.
2011.11.015
217. Abdoul H, Le Faou AL, Bouchez
J, Touzeau D, Lagrue G. Cannabis
cessation Interventions offered to
young French users: predictors
of follow-up. Encaphale (2012)
38(2):141–8. doi:10.1016/j.encep.
2011.04.007
218. Scott LA, Roxburgh A, Bruno
R, Matthews A, Burns L. The
impact of comorbid cannabis and
methamphetamine use on mental
health among regular ecstasy users.
Addict Behav (2012). doi:10.1016/
j.addbeh.2012.04.012
219. Friedmann PD, Green TC, Tax-
man FS, Harrington M, Rhodes
AG, Katz E, et al. Collaborative
behavioral management among
parolees: drug use, crime & re-
arrest in the Step’n Out random-
ized trial.Addiction (2011). doi:10.
1111/j1360-0443.2011.03769.x
220. Baker AL, Thornton LK, Hides L,
Dunlop A. Treatment of cannabis
use among people with psychotic
disorders: a critical review of ran-
domised control trials.Curr Pharm
Des (2012) 71(3):247–54. doi:10.
4088/JCP.09r05119gry
221. Buckner JD, Zvolensky MJ,
Schmidt NB. Cannabis-related
impairment and social anxiety:
the roles of gender and cannabis
use motives. Addict Behav (2012).
doi:10.1016/j.addbeh.2012.06.013
222. Carroll KM, Nich C, Lapaglia DM,
Peters EN, Easton CJ, Petry NM.
Combining cognitive behavioral
therapy and contingency manage-
ment to enhance their effects in
treating cannabis dependence: less
can be more, more or less. Addic-
tion (2012) 107(9):1650–9. doi:10.
1111/j.1360-0443.2012.03877.x
Frontiers in Public Health | Child Health and Human Development October 2013 | Volume 1 | Article 42 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greydanus et al. Marijuana: current concepts
223. Hendriks V, van der Schee E,
Blanken P. Matching adolescents
with a cannabis use disorder to
multidimensional family therapy
or cognitive behavioral therapy:
treatment effect moderators in a
randomized controlled trial. Drug
Alcohol Depend (2012). doi:10.
1016/j.drugalcdep.2012.03.023
224. Baker AL, Hides L, Lubman
DI. Treatment of cannabis use
among people with psychotic
or depressive disorders: a sys-
temic review. J Clin Psychiatry
(2010) 71(3):247–54. doi:10.4088/
JCP.09r05119gry
225. Gates PJ, Norberg MM, Copeland
J, Digiusto E. Randomised con-
trolled trial of a noval cannabis
use intervention delivered by tele-
phone. Addiction (2012). doi:10.
1111/j.1360-0443.2012.03953.x
226. Lindsey WT, Stewart D, Chil-
dress D. Drug interactions between
common illicit drugs and pre-
scription therapies. Am J Drug
Alcohol Abuse (2012). doi:10.3109/
00952990.2011.643997
227. Vandrey R, Haney M. Pharma-
cotherapy for cannabis depen-
dence: how close are we? CNS
Drugs (2009) 23:543–53. doi:10.
2165/00023210-200923070-00001
228. Hjorthøj C, Fohlmann A,
Nordentoft M. Treatment of
cannabis use disorders in peo-
ple with schizophrenia spectrum
disorders-a systemic review.Addict
Behav (2009) 34(6-7):520–5.
doi:10.1016/j.addbeh.2009.02.001
229. Agrawal A, Verweil KJ, Gillespie
NA, Health AC, Lessov-Schlaggar
CN, Martin CN, et al. The genetics
of addiction – a translational per-
spective. Transl Psychiatry (2012)
2:e140. doi:10.1038/tp.2012.54
230. Crippa JA, Derenusson GN, Cha-
gas MH, Atakan Z, Matin-Santos
R, Zuardi AW, et al. Pharmacologic
interventions in the treatment of
the acute effects of cannabis: a
systemic review of literature.Harm
Reduct J (2012) 9(1):7. doi:10.
1186/1477-7517-9-7
231. Crippa JA, Hallak JE, Machado-
de-Sousa JP, Queiroz RH, Berga-
maschi M, Chagus MH, et al.
Cannabidiol for the treatment of
cannabis withdrawal syndrome: a
case report. J Clin Pharm Ther
(2012). doi:10.1111/jcpt.12018
232. Vandrey R, Stitzer ML, Mintzer
MZ, Huestis MA, Murray JA, Lee
D. The dose effects of short-term
dronabinol (oral THC) mainte-
nance in daily cannabis users.
Drug Alcohol Depend (2012). doi:
10.1016/j.drugalcdep.2012.08.001
233. Haney M, Hart CL, Vosburg KD.
Effects of THC and lofexidine
in a human laboratory model of
marijuana withdrawal and relapse.
Psychopharmacology (Berl) (2008)
197:157–68. doi:10.1007/s00213-
007-1020-8
234. Bedi G, Cooper ZD, Haney M.
Subjective, cognitive and car-
diovascular dose-effect profile
of nabilone and dronabinol in
marijuana smokers. Addict Biol
(2012). doi:10.1111/j.1369-1600.
2011.00427.x
235. Kleinloog D, Liem-Moolenaar
M, Jacobs G, Klaassen E,
de Kam M, Hijman R, et
al. Does olanzapine inhibit
the psychomimetic effects of
{Delta} 9-tetrahydrocannabinol?
J Psychopharmacol (2012).
doi:10.1177/0269881112446534
236. Sarnyai Z. Oxytocin and neuroad-
aptation to cocaine. Prog Brain Res
(1998) 119:449–66. doi:10.1016/
S0079-6123(08)61587-3
237. Baskerville TA, Douglas AJ.
Dopamine and oxytocin inter-
actions underlying behaviors:
potential contributions to behav-
ioral disorders. CNS Neurosci Ther
(2010) 16(3):e92–123. doi:10.
1111/j.1755-5949.2010.00154.x
238. McGregor IS, Bowen MT. Break-
ing the loop: oxytocin as a poten-
tial treatment for drug addiction.
Horm Behav (2011). doi:10.1016/j.
yhbeh.2011.12.001
239. Gray KM, Carpenter MJ, Baker
NL, Desantis SM, Kryway E,
Hartwell KJ, et al. A double-
blind randomized controlled trail
of N-acetylcysteine in cannabis-
dependent adolescents. Am J Psy-
chiatry (2012). doi:10.1176/appi.
ajp.2012.12010055
240. Weinstein AM, Gorelicki DA.
Pharmacologic treatment of
cannabis dependence. Curr
Pharm Des (2011) 17(14):1351–8.
doi:10.2174/138161211796150846
241. Pertwee RG. Cannabis and
cannabinoids: pharmacology
and rationale for clinical use.
Forsch Komplementarmed (1999)
(Suppl 3):12–5. doi:10.1159/
000057150
242. Svrakic DM, Lustman PJ, Mallya A,
Lynn TA, Finney R, Svrakic NM.
Legalization, decriminalization &
medicinal use of cannabis: a scien-
tific and public health perspective.
MoMed (2012) 109(2):90–8.
243. Beaulieu P, Rice AS. The phar-
macology of cannabinoids deriv-
atives: are there applications to
treatment of pain? Ann Fr Anesth
Reanim (2002) 21(6):493–508.
doi:10.1016/S0750-7658(02)
00663-9
244. Lee MC, Ploner M,Wiech K, Bingel
U, Wanigasekera V, Brooks J, et al.
Amygdala activity contributes to
the dissociative effect of cannabis
on pain perception. Pain (2013)
154(1):124–34. doi:10.1016/j.pain.
2012.09.017
245. Richardson GA, Larkby C, Gold-
schmidt L, Day NL. Adolescent
initiation of drug use effects
of prenatal cocaine exposure. J
Am Acad Child Adolesc Psychiatry
(2013) 52(1):37–46. doi:10.1016/j.
jaac.2012.10.011
246. Mercolini L, Mandrioli R, Sorella
V, Somaini L, Giocondi D, Serpel-
loni G, et al. Dried blood spots:
liquid chromatography-mass
spectrometry analysis of delta-
9-tetrahydrocannabinol and
its main metabolites. J Chro-
matogr A (2013) 1271(1):33–40.
doi:10.1016/j.chroma.2012.11.030
247. Danovitch I, Gorelick DA. State
of the art treatments for cannabis
dependence. Psychiatr Clin North
Am (2012) 35(2):309–26. doi:10.
1016/j.psc.2012.03.003
248. Forray A, Sofuoglu M. Future
pharmacologic treatments for sub-
stance use disorders.Br JClinPhar-
macol (2012). doi:10.1111/j.1365-
2125.2012.04474.x
249. Greydanus DE, Feucht C, Hawver
EK. Substance abuse and adoles-
cence. Int J Child Health Hum Dev
(2012) 5(2):149–79.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 30 July 2013; accepted: 23 Sep-
tember 2013; published online: 10 Octo-
ber 2013.
Citation: Greydanus DE, Hawver EK,
Greydanus MM and Merrick J (2013)
Marijuana: current concepts. Front. Pub-
lic Health 1:42. doi:10.3389/ fpubh.2013.
00042
This article was submitted to Child
Health and Human Development, a
section of the journal Frontiers in Public
Health.
Copyright © 2013 Greydanus, Hawver,
Greydanus andMerrick. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) or licensor
are credited and that the original publica-
tion in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.
www.frontiersin.org October 2013 | Volume 1 | Article 42 | 17
